[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1450
1. Strasser H, Amann K, Schrott KM, Krause FS: Solitary metastasis of a Merkel cell tumor to the urinary bladder. Anticancer Res; 2008 Mar-Apr;28(2B):1361-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary metastasis of a Merkel cell tumor to the urinary bladder.
  • The primary Merkel cell carcinoma, a neuroendocrine tumor, mostly appears on skin areas exposed to light.
  • Lymphogenic and hematogenic metastasizing to the urinary bladder is rare, however infiltrating tumor growth into the urinary bladder occurs more frequently.
  • In urology, the Merkel cell tumor has been detected only sporadically, while infiltration of the bladder has been described in three cases worldwide.
  • We report the case of a patient with a single metastasis of a Merkel cell tumor in the urinary bladder, after excision of the femoral primary cancer two years earlier.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Skin Neoplasms / pathology. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505079.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Fakiha M, Letertre P, Vuillez JP, Lebeau J: Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther; 2010 Jul-Sep;6(3):382-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of Merkel cell tumor after somatostatin analog treatment.
  • We recently treated one patient presenting with a disseminated non-operable Merkel cell carcinoma (MCC) by lanreotide (somatostatin analog), with a complete remission of the disease and a follow up of 17 months.
  • We present in this paper a case report with a review of the utilization of somatostatin analogues in the treatment of MCC.
  • [MeSH-major] Carcinoma, Merkel Cell / drug therapy. Remission Induction. Skin Neoplasms / drug therapy. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cancer Res Ther. 2012 Jul-Sep;8(3):460 [23174738.001]
  • (PMID = 21119285.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


3. Kuroda S, Tanimoto K, Izawa T, Fujihara S, Koolstra JH, Tanaka E: Biomechanical and biochemical characteristics of the mandibular condylar cartilage. Osteoarthritis Cartilage; 2009 Nov;17(11):1408-15
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomechanical and biochemical characteristics of the mandibular condylar cartilage.
  • The articular surface of the mandibular condyle is covered with cartilage that is composed mainly of collagen fibers and proteoglycans.
  • This construction results in a viscoelastic response to loading and enables the cartilage to play an important role as a stress absorber during function.
  • To understand its mechanical functions properly, and to assess its limitations, detailed information about the viscoelastic behavior of the mandibular condylar cartilage is required.
  • The purpose of this paper is to review the fundamental concepts of the biomechanical behavior of the mandibular condylar cartilage.
  • Part 1 is a brief introduction of the structure and function of the mandibular condylar cartilage.
  • In Part 2, the biochemical composition of the mandibular condylar cartilage is summarized.
  • Part 3 explores the biomechanical properties of the mandibular condylar cartilage.
  • Finally, Part 4 relates this behavior to the breakdown mechanism of the mandibular condylar cartilage which is associated with the progression of osteoarthritis in the TMJ.

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477310.001).
  • [ISSN] 1522-9653
  • [Journal-full-title] Osteoarthritis and cartilage
  • [ISO-abbreviation] Osteoarthr. Cartil.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid
  • [Number-of-references] 97
  •  go-up   go-down


Advertisement
4. Pilloni L, Manieli C, Senes G, Ribuffo D, Faa G: Merkel cell carcinoma with an unusual immunohistochemical profile. Eur J Histochem; 2009 Dec 29;53(4):e33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma with an unusual immunohistochemical profile.
  • The clinical and morphological picture of Merkel cell carcinoma (MCC) may be rather challenging; therefore, the immunohistochemical profile plays a relevant role in confirming the microscopic diagnosis.
  • A panel of antibodies including cytokeratins 20, 7 and epithelial membrane antigen, and neuron-specific enolase is used in confirming the morphological diagnosis of MCC.
  • The majority of MCCs express CK20 and are CK7-negative.
  • Herein, we present a case of primary cutaneous neuroendocrine carcinoma with an atypical immunohistochemical pattern.
  • The skin tumor was excided, formalin-fixed and paraffinembedded.
  • Tissue sections were immunostained with a panel of antibodies routinely utilized in complex primary skin tumors for evidencing epithelial and neuroendocrine differentiation of tumor cells.
  • The neuroendocrine differentiation of tumor cells was evidenced by their immunoreactivity for synaptophysin, chromograninA and neuron-specific enolase.
  • Tumor cells also showed diffuse cytoplasmic staining for CK7.
  • Our data, together with previous rare reports of CK20-/CK7+ MCCs, lay stress on the importance of routinely utilizing a panel of antibodies in the differential diagnosis of complex primary carcinomas of the skin and may have important implications in expanding the differential diagnosis of skin tumors.
  • In particular, caution should be taken in excluding the diagnosis of MCC only on the basis of the absence of reactivity of tumor cells for CK20, favouring the wrong diagnosis of less aggressive skin tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Merkel Cell / chemistry. Carcinoma, Merkel Cell / pathology. Keratin-20 / analysis. Keratin-7 / analysis. Skin Neoplasms / chemistry. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 2000 Feb;22(1):65-9 [10698220.001]
  • [Cites] J Cutan Pathol. 2007 Dec;34(12):918-23 [18001414.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):310-5 [11127923.001]
  • [Cites] Pathologica. 2001 Dec;93(6):640-4 [11785114.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):588-98 [11786590.001]
  • [Cites] Histopathology. 2002 Mar;40(3):230-6 [11895488.001]
  • [Cites] Am J Dermatopathol. 1980 Summer;2(2):101-19 [7246977.001]
  • [Cites] Am J Dermatopathol. 1982 Dec;4(6):497-500 [7165057.001]
  • [Cites] Pathol Annu. 1984;19 Pt 2:1-30 [6209606.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):109-16 [2579592.001]
  • [Cites] Lab Invest. 1985 Apr;52(4):334-53 [2580118.001]
  • [Cites] Differentiation. 1985;30(2):165-75 [3007249.001]
  • [Cites] Dermatologica. 1988;177(1):1-10 [3141225.001]
  • [Cites] J Invest Dermatol. 1995 Jun;104(6):910-5 [7769257.001]
  • [Cites] Exp Dermatol. 1995 Dec;4(6):365-71 [8608344.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2589-95 [10375107.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):5 [15611999.001]
  • [Cites] Am J Dermatopathol. 2006 Apr;28(2):99-104 [16625069.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2493-9 [10856110.001]
  • (PMID = 22073365.001).
  • [ISSN] 2038-8306
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7
  • [Other-IDs] NLM/ PMC3167334
  • [Keywords] NOTNLM ; CK20 negative / CK7 positive. / Merkel cell carcinoma / immunohistochemical profile
  •  go-up   go-down


5. Bhalekar MR, Desale SS, Madgulkar AR: Synthesis of MCC-PEG conjugate and its evaluation as a superdisintegrant. AAPS PharmSciTech; 2010 Sep;11(3):1171-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis of MCC-PEG conjugate and its evaluation as a superdisintegrant.
  • PEGylated conjugate of microcrystalline cellulose (MCC) was synthesized by reacting MCC with polyethylene glycol (PEG) 200 in the presence of catalyst at elevated temperature.
  • Conjugation between MCC and PEG was confirmed by FT-IR and (1)H NMR studies.
  • The physico-chemical properties of conjugate were compared against MCC.
  • After comparing its results with that of commercial superdisintegrants, it can be concluded that MCC-PEG conjugate can prove to be a good superdisintegrant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pharm Biopharm. 2000 Mar;49(2):151-9 [10704898.001]
  • [Cites] Int J Pharm. 2002 Jan 31;232(1-2):69-80 [11790491.001]
  • [Cites] AAPS PharmSciTech. 2000;1(3):E18 [14727904.001]
  • [Cites] Drug Dev Ind Pharm. 2008 Apr;34(4):373-83 [18401779.001]
  • [Cites] J Pharm Sci. 1975 Mar;64(3):447-51 [1151632.001]
  • [Cites] J Pharm Pharmacol. 1987 Jun;39(6):495-6 [2886614.001]
  • [Cites] J Pharm Sci. 1974 Mar;63(3):473-4 [4820391.001]
  • (PMID = 20661675.001).
  • [ISSN] 1530-9932
  • [Journal-full-title] AAPS PharmSciTech
  • [ISO-abbreviation] AAPS PharmSciTech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Emulsions; 0 / Excipients; 0 / microcrystalline cellulose; 30IQX730WE / Polyethylene Glycols; 9004-34-6 / Cellulose
  • [Other-IDs] NLM/ PMC2974116
  •  go-up   go-down


6. Cekanova M, Lee SH, McEntee MF, Baek SJ: MCC-555-induced NAG-1 expression is mediated in part by KLF4. Eur J Pharmacol; 2010 Jul 10;637(1-3):30-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MCC-555-induced NAG-1 expression is mediated in part by KLF4.
  • Peroxisome proliferator-activated receptor gamma (PPARgamma) plays a central role in cell differentiation, metabolism and tumorigenesis.
  • We have investigated the therapeutic properties of 5-[[6-[(2-fluorophenyl)-methoxy]-2-napthalenyl]-methyl]-2,4-thiazolidinedione (MCC-555) a PPARgamma agonist in human colorectal cancer cells.
  • To elucidate the molecular mechanism(s), by which MCC-555 exerts its effects on the human colorectal cancer cells, we have analyzed the expression of two pro-apoptotic proteins, Krüppel-like factor 4 (KLF4) and nonsteroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1).
  • MCC-555-induced expression of the transcription factor, KLF-4 was blocked by a PPARgamma specific antagonist GW9662 in PPARgamma-dependent manner in HCT-116 cells.
  • We confirmed that PPARgamma agonists-induced NAG-1 expression was abolished using KLF4 siRNA in HCT-116 cells.
  • Subsequently, KLF4 expression enhances the NAG-1 promoter activity in HCT-116 cells, and functional KLF4 binding sites in the NAG-1 promoter were also identified.
  • MCC-555, a PPARgamma agonist induced the expression of Klf4 mRNA and protein in murine intestinal tumors from MCC-555-treated mice, as assessed by RT-PCR and immunohistochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • [Cites] Int J Cancer. 2009 Dec 15;125(12):2802-9 [19551868.001]
  • [Cites] Mol Cancer Ther. 2008 Dec;7(12):3739-50 [19074849.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):20127-35 [10777512.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):901-8 [11259636.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33384-92 [11445565.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):425-34 [11895857.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jun;301(3):1126-31 [12023546.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5845-53 [12475986.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):958-64 [12615709.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3424-30 [12776194.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1508-20 [14977855.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Mol Cell. 1999 Jun;3(6):799-804 [10394368.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 4;328(1):63-9 [15670751.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1412-22 [15608671.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2746-54 [15805274.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):935-45 [15825076.001]
  • [Cites] Mol Pharmacol. 2005 Nov;68(5):1203-13 [16077033.001]
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1074-82 [16244670.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1352-61 [16731769.001]
  • [Cites] Pathol Res Pract. 2006;202(8):585-9 [16814484.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2324-36 [16985067.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):851-61 [17032502.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1553-60 [17101328.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1588-98 [17513608.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7147-54 [17671182.001]
  • [Cites] Pharmacol Res. 2007 Aug;56(2):91-8 [17428674.001]
  • [Cites] Carcinogenesis. 2007 Nov;28(11):2337-46 [17724373.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):809-19 [18360708.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2779-87 [18790758.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • (PMID = 20385121.001).
  • [ISSN] 1879-0712
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108975-03; United States / NCI NIH HHS / CA / R01 CA108975; United States / NCI NIH HHS / CA / R01-CA108975; United States / NCI NIH HHS / CA / CA108975-03; United States / NCI NIH HHS / CA / R01 CA108975-04; United States / NCI NIH HHS / CA / R01 CA108975-02; United States / NCI NIH HHS / CA / CA108975-02; United States / NCI NIH HHS / CA / CA108975-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GKLF protein; 0 / Growth Inhibitors; 0 / Kruppel-Like Transcription Factors; 0 / NAG protein, human; 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Thiazolidinediones; 0 / Transcription Factors; 161600-01-7 / netoglitazone; 2295-31-0 / 2,4-thiazolidinedione
  • [Other-IDs] NLM/ NIHMS195409; NLM/ PMC2878920
  •  go-up   go-down


7. Slack MH, Cade S, Schapira D, Thwaites RJ, Crowley-Luke A, Southern J, Borrow R, Miller E: DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation. Arch Dis Child; 2005 Apr;90(4):338-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation.
  • AIMS: To describe the immune response of preterm infants to combined diphtheria/tetanus/5 component acellular pertussis-Haemophilus influenzae type b inactivated polio vaccine (DT5aP-Hib-IPV) and meningococcal serogroup C conjugate vaccine (MCC) under accelerated schedule.
  • DT5aP-Hib-IPV and MCC vaccines were given at 2, 3, and 4 months.
  • After three doses of vaccines Hib polysaccharide IgG geometric mean concentration (GMC) was 1.21 microg/ml with 80% > or =0.15 microg/ml; MCC serum bactericidal assay geometric mean titre (GMT) was 1245 with 100% > or =8.
  • CONCLUSION: Preterm infants immunised with DT5aP-Hib-IPV and MCC vaccines show IgG responses to Hib and MCC greater than seen historically in both term and preterm infants with a DT3aP-Hib vaccine, and for pertussis antigens and poliovirus type 1 responses similar to that seen in term infants immunised with DT5aP-Hib-IPV.

  • MedlinePlus Health Information. consumer health - Premature Babies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2000 Jul;83(1):F24-7 [10873167.001]
  • [Cites] J Infect Dis. 1999 Jun;179(6):1569-72 [10228085.001]
  • [Cites] J Infect Dis. 1999 Aug;180(2):538-41 [10395878.001]
  • [Cites] Pediatr Infect Dis J. 2002 Mar;21(3):182-6 [12005078.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1521-3 [12737866.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F57-60 [14711858.001]
  • [Cites] J Pediatr. 1983 Dec;103(6):917-9 [6644426.001]
  • [Cites] J Pediatr. 1985 Aug;107(2):184-8 [3874942.001]
  • [Cites] J Pediatr. 1992 May;120(5):686-9 [1315853.001]
  • [Cites] J Infect. 1993 Sep;27(2):143-50 [8228295.001]
  • [Cites] Arch Dis Child. 1995 Mar;72(3):230-2 [7741570.001]
  • [Cites] Pediatrics. 1995 Jul;96(1 Pt 1):18-22 [7596716.001]
  • [Cites] Lancet. 1996 Dec 21-28;348(9043):1688-92 [8973430.001]
  • [Cites] Lancet. 1997 Nov 29;350(9091):1569-77 [9393335.001]
  • [Cites] Infect Immun. 1998 May;66(5):2093-8 [9573094.001]
  • [Cites] Pediatrics. 1999 Jan;103(1):25-30 [9917435.001]
  • [Cites] J Infect Dis. 2001 Dec 15;184(12):1617-20 [11740740.001]
  • (PMID = 15781918.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DT5aP-Hib-IPV vaccine; 0 / Diphtheria-Tetanus-Pertussis Vaccine; 0 / Haemophilus Vaccines; 0 / Immunoglobulin G; 0 / Meningococcal Vaccines; 0 / Poliovirus Vaccine, Inactivated; 0 / Vaccines, Combined; 0 / diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine; 0 / serogroup C meningococcal conjugate vaccine
  • [Other-IDs] NLM/ PMC1720330
  •  go-up   go-down


8. Mikolyzk DK, Bednar MS: Merkel cell tumor of the hand: report of two cases. J Hand Surg Am; 2008 Mar;33(3):404-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumor of the hand: report of two cases.
  • Merkel cell carcinoma is a rare cutaneous neuroendocrine neoplasm.
  • Often located on the head and neck, reports of Merkel cell carcinoma in the hand are extremely limited.
  • In this article, we review 2 cases of Merkel cell carcinoma of a digit treated with ray resection and sentinel lymph node dissection with greater than 5 years of follow-up.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343299.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Ivan D, Bengana C, Lazar AJ, Diwan AH, Prieto VG: Merkel cell tumor in a trichilemmal cyst: collision or association? Am J Dermatopathol; 2007 Apr;29(2):180-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumor in a trichilemmal cyst: collision or association?
  • Histologic examination revealed a dermal proliferation of monomorphous cells arranged in trabeculae, nests, and sheets with an infiltrative growth pattern.
  • The cells had a high nuclear-cytoplasmic ratio, finely granular nuclear chromatin, and nuclear molding.
  • Numerous mitotic figures, apoptotic cells, and individual cell necrosis were present; lymphovascular invasion was identified.
  • The tumor was attached, demonstrating pagetoid intraepithelial migration, to a follicular cyst lined by squamous epithelium, lacking a granular cell layer and filled with compact keratinous content, diagnostic of trichilemmal cyst.
  • Immunohistochemical study revealed that tumor cells expressed pan-cytokeratin (CK), chromogranin, synaptophysin, neuron-specific enolase, and CK20 (dotlike staining pattern), thus supporting the diagnosis of Merkel cell carcinoma.
  • The association of Merkel cell carcinoma with a cyst is an exceptionally rare occurrence.
  • As a result of the prominent involvement of the cyst wall by tumor cells, we favor that in this case carcinoma arose in the trichilemmal cyst rather than being a collision tumor.
  • This hypothesis is also supported by the recent observation that Merkel cells are frequently present within normal hair follicles, especially in the isthmic portion that corresponds with the area of origin of the trichilemmal cyst.
  • [MeSH-major] Carcinoma, Merkel Cell / etiology. Epidermal Cyst / complications. Hair Follicle / pathology. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Chromogranins / analysis. Hair Diseases / complications. Hair Diseases / pathology. Humans. Immunohistochemistry. Keratin-20 / analysis. Male. Merkel Cells / pathology. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414443.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


10. Andres C, Belloni B, Puchta U, Sander CA, Flaig MJ: Prevalence of MCPyV in Merkel cell carcinoma and non-MCC tumors. J Cutan Pathol; 2010 Jan;37(1):28-34
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of MCPyV in Merkel cell carcinoma and non-MCC tumors.
  • BACKGROUND: Merkel cell polyomavirus (MCPyV) is the likely causative agent of Merkel cell carcinoma (MCC).
  • However, the prevalence of MCPyV in non-MCC population and its possible role in the pathogenesis of other skin cancers are not known yet.
  • METHODS: A molecular pathology study was performed in 33 MCC samples and 33 age- and sex-matched samples of sun exposed non-MCC tumors [12 seborrheic keratoses (SK), 11 basal cell carcinomas (BCC) and 10 lentigo maligna melanomas (LMM)].
  • All tumors were analyzed for presence of MCPyV-DNA by polymerase chain reaction (PCR) and Southern-Blot hybridization of PCR products.
  • RESULTS: MCPyV sequences were detected in 21 MCC samples (64%) and in 2 non-MCC tumors of sun exposed skin (6%; both SK-patients).
  • CONCLUSION: We were able to confirm prior data on prevalence of MCPyV-DNA in MCC.
  • Furthermore, a female predominance of MCPyV-positive MCC-patients was detected.
  • Speculative, prevalence of MCPyV in an age- and sex-matched non-MCC population could average up to 6%.
  • [MeSH-major] Carcinoma, Merkel Cell / virology. Hutchinson's Melanotic Freckle / virology. Neoplasms, Basal Cell / virology. Polyomavirus / isolation & purification. Polyomavirus Infections / complications. Skin Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Viral, Tumor / analysis. Comorbidity. DNA, Neoplasm / analysis. DNA, Viral / analysis. Female. Germany / epidemiology. Humans. Keratosis, Seborrheic / pathology. Keratosis, Seborrheic / virology. Male. Middle Aged. Sex Factors. Skin / pathology. Skin / virology. Skin Aging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 19615033.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


11. Requena L, Jaqueti G, Rütten A, Mentzel T, Kutzner H: Merkel cell carcinoma within follicular cysts: report of two cases. J Cutan Pathol; 2008 Dec;35(12):1127-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma within follicular cysts: report of two cases.
  • Merkel cell carcinoma is a rare cutaneous neoplasm of unknown histogenesis.
  • Several reports have described the association of Merkel cell carcinoma of the skin with other cutaneous neoplasms within the same lesion, and there are also reports describing three examples of Merkel cell carcinoma within follicular cysts.
  • We describe two examples of Merkel cell carcinoma developed within epithelial cysts.
  • Neoplastic cells of Merkel cell tumor expressed immunoreactivity for chromogranin, synaptophysin, neuron-specific enolase, CAM 5.2 and cytokeratin 20, the last two markers showing the characteristic paranuclear dot-like pattern.
  • In contrast, the epithelial wall lining the cyst and surrounding Merkel cell tumor only expressed immunoreactivity for cytokeratin MNF116.
  • The description of five cases of Merkel cell carcinoma within follicular cysts, including the two cases of this report, support some relationship between Merkel cell tumor and the hair follicle.
  • [MeSH-major] Carcinoma, Merkel Cell / complications. Carcinoma, Merkel Cell / pathology. Follicular Cyst / complications. Follicular Cyst / pathology. Skin Neoplasms / complications. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988316.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


12. Ng G, Lenehan B, Street J: Metastatic Merkel cell carcinoma of the spine. J Clin Neurosci; 2010 Aug;17(8):1069-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Merkel cell carcinoma of the spine.
  • Merkel cell carcinoma is a rare neuroendocrine malignancy, primarily affecting sun-exposed skin.
  • We report a 73-year-old male who presented with rapidly progressive paraplegia 6 months following excision of a primary cutaneous Merkel cell lesion.
  • Unfortunately, this patient died 1 month postoperatively, succumbing to overwhelming metastatic disease.
  • This report highlights the locally aggressive nature of metastatic Merkel cell tumor and the very poor prognosis in those patients who develop spinal column metastases.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Skin Neoplasms / pathology. Spinal Neoplasms / secondary. Thoracic Vertebrae / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20488712.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


13. Petković M, Krstulja M, Radic J, Zamolo G, Muhvić D, Lovasic I, Kujundzic M, Franko A: Merkel cell carcinoma arising in the ear canal. Int J Surg Pathol; 2008 Jul;16(3):337-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma arising in the ear canal.
  • A case of rare tumor, Merkel cell carcinoma, located in the ear canal of a 25-year-old woman is presented.
  • A polypoid tumor mass was extirpated, and tympanoplasty was done at the first operation, whereas at the second operation, all the bones of the ear canal were removed.
  • Epitympanum and cavum were filled with tumor, and the tumor mass was removed in toto.
  • The histopathology and immunohistochemical staining characteristics of tumor confirmed the presence of Merkel cell tumor.
  • Postoperatively, radiation therapy to the tumor bed was completed.
  • There was no clinical or radiographic evidence of recurrence or metastasis of Merkel cell tumor for 3 years.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Ear Canal / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387993.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Daser A, Thangavelu M, Pannell R, Forster A, Sparrow L, Chung G, Dear PH, Rabbitts TH: Interrogation of genomes by molecular copy-number counting (MCC). Nat Methods; 2006 Jun;3(6):447-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrogation of genomes by molecular copy-number counting (MCC).
  • Molecular copy-number counting (MCC) uses PCR to interrogate miniscule amounts of genomic DNA and allows progressive delineation of DNA content to within a few hundred base pairs of a genomic alteration.
  • As an example, we have located the junctions of a recurrent nonreciprocal translocation between chromosomes 3 and 5 in human renal cell carcinoma, facilitating cloning of the breakpoint without recourse to genomic libraries.
  • MCC is a fast and flexible method for characterizing a wide range of chromosomal aberrations.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Chromosome Mapping / methods. Gene Dosage / genetics. Haplotypes / genetics. Kidney Neoplasms / genetics. Polymerase Chain Reaction / methods. Sequence Analysis, DNA / methods
  • [MeSH-minor] DNA Mutational Analysis / methods. Genetic Predisposition to Disease / genetics. Genome, Human / genetics. Humans. Phenotype. Polymorphism, Single Nucleotide / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Methods. 2006 Jun;3(6):427-8 [16721375.001]
  • [ErratumIn] Nat Methods. 2006 Jul;3(7):579
  • (PMID = 16721378.001).
  • [ISSN] 1548-7091
  • [Journal-full-title] Nature methods
  • [ISO-abbreviation] Nat. Methods
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105131672; United Kingdom / Medical Research Council / / MC/ U105178807
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Bateman C: Dysfunctional MCC under legal threat. S Afr Med J; 2010 May;100(5):274, 276
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysfunctional MCC under legal threat.
  • The dysfunctional Medicines Control Council (MCC), which has registered less than half of all medicine applications to it over the past 7 years, has become a life-threatening risk to patients and is now under legal threat from stakeholders.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460014.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


16. Levi F, Innominato P, Poncet A, Moreau T, Iacobelli S, Focan C, Garufi C, Bjarnason G, Adam R, Giacchetti S, ARTBC Chronotherapy Group: Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT). J Clin Oncol; 2009 May 20;27(15_suppl):4112

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT).
  • : 4112 Background: Gender predicted for the most effective schedule in a RT of ChronoFLO vs CONV against MCC: overall survival (OS) was significantly increased in men on chronoFLO vs FOLFOX, whereas the reverse was found in women (Giacchetti, JCO 2006).
  • METHODS: To assess the relevance of gender for patient (pt) outcome, meta-analysis was performed on individual pt data (IPD) from 3 RT in 845 MCC pts treated with chronoFLO vs CONV (346 F, 499 M at 36 centers in 1990-2002)(Lévi, JNCI 1994; Lancet 1997).
  • CONCLUSIONS: This IPD meta-analysis of 3 RT in MCC with a minimum follow up of 5 years confirms that men benefit from chronoFLO as compared to CONV delivery, with regard to long term outcome and medico-surgical strategy.
  • ChronoFLO should be preferred to conventional oxaliplatin-5-FU-LV schedules in men with MCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961226.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Andea AA, Patel R, Ponnazhagan S, Kumar S, DeVilliers P, Jhala D, Eltoum I, Manne U, Siegal G: Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis. J Clin Oncol; 2009 May 20;27(15_suppl):6027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis.
  • Recently, a novel polyoma virus, named Merkel cell polyomavirus (MCV) was identified integrated to the genome of 6 of 10 fresh frozen samples of MCC.
  • These findings suggest an involvement of MCV in the pathogenesis of MCC.
  • Because MCC is a rare tumor, the most readily available tissue is archival formalin-fixed, paraffin-embedded (FFPE) material.
  • In this study we evaluated the presence of MCV in FFPE tissue and correlated its presence with tumor progression.
  • METHODS: Representative FFPE specimens from 18 tumors belonging to 14 patients with a diagnosis of MCC were retrieved.
  • For clinical outcome analysis we used our MCC database containing 40 patients from 1997 to 2008 with a median follow-up interval of 20 months (range 1-108 months).
  • RESULTS: We detected MCV amplicons in 8 of 18 analyzed tumors (44.4%) from 7 of 14 cases (50%).
  • PCR products from the T antigen portion of MCV were found in 6 of 18 tumors (33.3%) and from the VP1 gene in 2 of 18 tumors (11.1%).
  • For 3 patients, MCV detection was performed in both the primary and metastatic tumors.
  • In one of these the virus was found in both lesions while in the other 2 only the primary tumor demonstrated the virus.
  • Two- and 5-year survival rates for the MCCs containing the virus were 47.6% and 0% respectively while for the rest of the cases in our database 2- and 5-year survival rates were 61.6% and 40.8% respectively; the difference did not reach however, statistical significance (p = 0.3).
  • We also found that the tumors harboring MCV exhibit a trend for more aggressive behavior compared to the rest of MCCs.
  • These findings suggest that MCV might have an etiologic role in carcinogenesis or tumor progression in MCC.
  • Further studies investigating the biological significance of MCV integration in the human genome and the presence of MCV in other neuroendocrine tumors are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Vrdoljak E, Omrcen T, Hrabar A: Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer (MCC). J Clin Oncol; 2009 May 20;27(15_suppl):e15074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer (MCC).
  • : e15074 Background: The aim of this prospective study was to evaluate efficacy and safety of bevacizumab in combination with capecitabine as first line treatment in elderly patients with MCC.
  • METHODS: 40 elderly patients (median age 75 years) with MCC have been treated with bevacizumab in combination with capecitabine as their first line therapy.
  • 3 patients (7.5 %) had complete response, 19 patients (47.5 %) had partial response, 11 patients (27.5 %) had stable disease, 1 patient (2.5 %) progressed according to RECIST criteria and 6 patients (15%) were not evaluated yet.
  • CONCLUSIONS: This prospective phase II study has demonstrated that bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer is an effective and well-tolerated regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964570.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Flaherty LE, Sondak VK: A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331). J Clin Oncol; 2009 May 20;27(15_suppl):9056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331).
  • : 9056 Background: Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) frequently stains strongly for c-KIT (CD-117) expression.
  • We therefore evaluated imatinib mesylate as a treatment for MCC.
  • METHODS: Eligibility included patients with measurable metastatic or unresectable MCC with CD117 expression by immunostaining.
  • Two patients were ineligible (one was found not to express CD117 on central pathology review, and one lacked measurable disease).
  • In addition, stable disease was observed in 3 patients (9, 4 and 3 months).
  • All were attributed to tumor progression.
  • One patient achieved a partial response and another had prolonged disease stabilization while receiving treatment.
  • DNA sequencing of c-KIT was performed on tumor tissue from on a non- responding patient and the one patient with long-term stable disease (9 months).
  • The observed progression-free survival and overall survival were not adequate to conclude that this agent was active in advanced MCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962132.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Santomaggio A, Ricevuto E, Cannita K, Bruera G, Tudini M, Lanfiuti Baldi P, Mancini M, Porzio G, Marchetti P, Ficorella C: "Poker" schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4125

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Poker" schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study.
  • Thus we evaluated in a phase II study the addition of BEV to the triplet combination CPT-11/OHP/5-fluorouracil (5-FU) as first line chemotherapy in metastatic colorectal carcinoma (MCC).
  • METHODS: Main inclusion criteria: histologically diagnosis of colorectal cancer (CRC) with measurable disease; age 18-75 yrs; adequate bone marrow reserve and renal and hepatic function; no cardiac diseases; no uncontrolled hypertension; no thromboembolic diseases or coagulopathy, no preexisting bleeding diatheses.
  • Primary endpoint: OR.
  • In the overall 48 pts, 46 were assessable ITT: OR 80% (α0.05, CI +12), 2 complete and 35 partial responses, 4 stable disease and 5 progression.
  • Received-DI: CPT-11 84% of projected-DI, OHP 82%, 5-FU 85%, BEV 84%, per pt respectively.
  • Thus it may be considered as the most active first line treatment of MCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961244.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Coppola D, Nicosia S, Lee J, Kim J, Schildkraut J, Narod S, Sutphen R, Sellers T, Pal T: Interobserver and interlaboratory variability of mismatch repair protein expression in ovarian tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e17505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and interlaboratory variability of mismatch repair protein expression in ovarian tumors.
  • : e17505 Background: Immunohistochemistry (IHC) for mismatch repair (MMR) protein (MLH1, MSH2, MSH6) expression has been a useful strategy for identifying tumors with MMR deficiency.
  • METHODS: To assess inter-observer (IO) and inter-laboratory (IL) variability of MMR protein expression, 41 epithelial ovarian cancer (EOC) samples were arrayed in triplicate for construction of a tissue microarray (TMA).
  • Six slides were made from this donor TMA block, of which 3 were stained at the Moffitt Cancer Center (MCC) and 3 were stained at the University of South Florida (USF), using different lab procedures.
  • RESULTS: The CCC value for the IO analysis was 0.95 (for MCC-stained slides; 95% C.I.: 0.89-0.98) and 0.85 (for USF-stained slides; 95% C.I.: 0.66, 0.93), indicating excellent concordance.
  • These findings are of great clinical significance due to the widespread use of IHC as diagnostic, prognostic and therapeutic tools in cancer care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963241.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Bukhari MH, Byron E, Strosberg JR, Nasir NA, Henderson-Jackson E, Bui M, Hakam A, Domenico C, Kvols L, Nasir A: Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15616

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases.
  • : e15616 Background: Primary gastro-entero-pancreatic poorly differentiated neuroendocrine carcinomas (GEP-PDNECAs) are highly aggressive neoplasms with a very poor prognosis.
  • METHODS: Under an IRB-approved protocol, clinico-pathologic data were collected on 68 adult patients with GEP-PDNECA who had undergone biopsy / resection at MCC or outside institution.
  • DATA SOURCES: Pathology archives, consultation files, tumor registry and social security index.
  • All available slides were reviewed and tumors were histologically sub-typed.
  • Sites: Colo-rectum 39, pancreas 19, small intestine (SI) 4, stomach 3, colon/SI/pancreas 3.
  • Of 68 tumors 37 (54%) were classified as small cell carcinoma (SCCA), 16 (24%) large cell carcinoma (LCCA), 5 (7%) mixed small and large cell (MSLCCA) and 10 (15%) poorly differentiated carcinoma with neuroendocrine features (PDCA-NEF).
  • Tumors were positive for chromogranin in 38/65 (55%), synaptophysin in 62/67 (92%), and CD56 in 17/21 (81%) cases.
  • CONCLUSIONS: Diagnosis of GEP-PDNECA can be based on histo-morphologic features and expression of neuroendocrine markers.
  • Synaptophysin was the most sensitive marker; however, a panel of 2 or 3 neuroendocrine markers (Syn, Cg and CD56) may be more useful to avoid under-diagnosis of GEP-PDNECA, especially in the metastatic setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962728.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Torroni A, Loré B, Iannetti G: The importance of the head and neck region in regression of advanced MCC: a clinical report. J Craniofac Surg; 2007 Sep;18(5):1173-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of the head and neck region in regression of advanced MCC: a clinical report.
  • This paper presents the case of a 76-year-old woman who experienced a total regression of a Merkel cell carcinoma (MCC).
  • The primary site of the tumor was on her right eyebrow.
  • An incisional biopsy into the right parotid gland confirmed the diagnosis of MCC metastasis.
  • No surgical treatment was prescribed because of the advanced stage of the disease.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Eyebrows. Facial Neoplasms. Neoplasm Regression, Spontaneous. Parotid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912107.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


24. Singh M, Detamore MS: Tensile properties of the mandibular condylar cartilage. J Biomech Eng; 2008 Feb;130(1):011009
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tensile properties of the mandibular condylar cartilage.
  • Mandibular condylar cartilage plays a crucial role in temporomandibular joint (TMJ) function, which includes facilitating articulation with the temporomandibular joint disc and reducing loads on the underlying bone.
  • The cartilage experiences considerable tensile forces due to direct compression and shear.
  • The present study aims to quantify the biomechanical characteristics of the mandibular condylar cartilage to aid future three-dimensional finite element modeling and tissue engineering studies.
  • Porcine condylar cartilage was tested under uniaxial tension in two directions, anteroposterior and mediolateral, with three regions per direction.
  • The predominantly anteroposterior macroscopic fiber orientation in the fibrous zone of condylar cartilage correlated well with the biomechanical findings.
  • The condylar cartilage appears to be less stiff and less anisotropic under tension than the anatomically and functionally related TMJ disc.
  • The anisotropy of the condylar cartilage, as evidenced by tensile behavior and collagen fiber orientation, suggests that the shear environment of the TMJ exposes the condylar cartilage to predominantly but not exclusively anteroposterior loading.
  • [MeSH-major] Cartilage, Articular / physiology. Mandibular Condyle / physiology. Models, Biological

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298185.001).
  • [ISSN] 0148-0731
  • [Journal-full-title] Journal of biomechanical engineering
  • [ISO-abbreviation] J Biomech Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Song Y, Wu C, Wong RW, Rabie AB: Identification of the chondrogenic pathway in the mandibular condylar cartilage. Front Biosci (Landmark Ed); 2009;14:1932-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the chondrogenic pathway in the mandibular condylar cartilage.
  • To identify genetic expression of mandibular condylar cartilage during natural growth and under mechanical strain as a result of mandibular advancement.
  • Five of them were novel and have never been identified in mandibular condyles before.
  • Quantitative analysis using real-time PCR revealed that these genes were involved in different stages in chondrogenesis and played an important role in condylar growth.
  • [MeSH-major] Cartilage / growth & development. Jaw

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273174.001).
  • [ISSN] 1093-4715
  • [Journal-full-title] Frontiers in bioscience (Landmark edition)
  • [ISO-abbreviation] Front Biosci (Landmark Ed)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


26. Lewis KG, Weinstock MA, Weaver AL, Otley CC: Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol; 2006 Jun;142(6):693-700
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant local irradiation for Merkel cell carcinoma.
  • OBJECTIVES: To determine the effect of adjuvant local irradiation on (1) disease recurrence and (2) survival rates in Merkel cell carcinoma (MCC).
  • DATA SOURCES: An Ovid MEDLINE search (January 1966-May 26, 2004) was performed using the following criteria: group 1, "Merkel cell OR trabecular OR neuroendocrine skin OR APUDoma skin OR primary small cell skin OR primary undifferentiated skin OR endocrine skin OR neuroepithelial" AND group 2, "carcinoma OR tumor OR cancer" with mapping modifiers "-title, -abstract, -keyword, -subject heading."
  • (1) a histopathologic diagnosis of MCC;.
  • (2) a single, primary tumor arising on the skin, for which (3) the primary treatment was surgical excision (local excision, wide excision, or Mohs surgery) with or without the use of adjuvant irradiation (to the tumor bed);.
  • (5) during the postoperative follow-up period, disease recurrence, progression, and survival and/or duration of event-free interval was documented with (6) a minimum follow-up of 1 month.
  • In general, differences in overall (HR, 0.78; P = .16) and cause-specific (due to MCC: HR, 0.72; P = .14) survival rates between treatment groups did not reach statistical significance.
  • CONCLUSIONS: Surgery plus local adjuvant irradiation was associated with significantly lower rates of local and regional recurrence of MCC than surgery alone.
  • [MeSH-major] Carcinoma, Merkel Cell / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Jun;142(6):771-4 [16785382.001]
  • (PMID = 16785371.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


27. Shimizu T, Tsujigiwa H, Nagatsuka H, Nakano K, Okafuji N, Kurihara S, Nagai N, Kawakami T: Gene expression of Jagged2 in mandibular condylar cartilage development. Eur J Med Res; 2008 Jan 23;13(1):1-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of Jagged2 in mandibular condylar cartilage development.
  • Expression pattern of Jagged2 gene in mandibular condylar cartilage was examined by means of in situ hybridization (ISH) technique.
  • These results suggest that Jagged2 plays an essential role for mandibular condylar cartilage morphogenesis and development.
  • [MeSH-major] Cartilage / embryology. Gene Expression. Mandibular Condyle / embryology. Membrane Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226989.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Jag2 protein, mouse; 0 / Membrane Proteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


28. Tanaka E, Yamano E, Dalla-Bona DA, Watanabe M, Inubushi T, Shirakura M, Sano R, Takahashi K, van Eijden T, Tanne K: Dynamic compressive properties of the mandibular condylar cartilage. J Dent Res; 2006 Jun;85(6):571-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic compressive properties of the mandibular condylar cartilage.
  • The mandibular condylar cartilage plays an important role as a stress absorber during function.
  • To characterize the viscoelastic properties of the condylar cartilage, we performed dynamic indentation tests over a wide range of loading frequencies.
  • Ten porcine mandibular condyles were used; the articular surface was divided into 4 regions, anteromedial, anterolateral, posteromedial, and posterolateral.
  • [MeSH-major] Cartilage, Articular / physiology. Mandibular Condyle / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723658.001).
  • [ISSN] 0022-0345
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Kranz H, Jürgens K, Pinier M, Siepmann J: Drug release from MCC- and carrageenan-based pellets: experiment and theory. Eur J Pharm Biopharm; 2009 Oct;73(2):302-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug release from MCC- and carrageenan-based pellets: experiment and theory.
  • Microcrystalline cellulose (MCC) is a well-established pelletisation aid.
  • However, MCC pellets generally do not disintegrate, resulting in prolonged drug release, especially in the case of drugs with poor/low aqueous solubility.
  • The major objectives of this study were (i) to modify the prolonged matrix-type drug release from MCC pellets by addition of a disintegrant (croscarmellose Na) or pore former (PEG 6000), (ii) to evaluate carrageenan as potential alternative pelletisation aid for manufacturing high-dose immediate release pellets, and (iii) to better understand the underlying drug release mechanisms.
  • Drug release from MCC pellets was predominantly controlled by pure diffusion and limited drug solubility and could be quantitatively described using Fick's law.
  • Importantly, the apparent drug diffusivity could effectively be adjusted by adding small amounts of a disintegrant or pore former, allowing for release periods ranging from a few minutes to several hours.

  • Hazardous Substances Data Bank. THEOPHYLLINE .
  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465119.001).
  • [ISSN] 1873-3441
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Phthalazines; 0 / Pyridines; 0 / microcrystalline cellulose; 30IQX730WE / Polyethylene Glycols; 5DX9U76296 / vatalanib; 9000-07-1 / Carrageenan; 9004-32-4 / Carboxymethylcellulose Sodium; 9004-34-6 / Cellulose; C137DTR5RG / Theophylline
  •  go-up   go-down


30. Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A: Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem; 2008 Aug;19(8):1673-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
  • CD22 represents a promising target for antibody-drug conjugate therapy in the context of B cell malignancies since it rapidly internalizes, importing specifically bound antibodies with it.
  • To determine the pharmacokinetic parameters of anti-CD22-MCC-DM1 and MC-MMAF conjugates, various approaches to quantifying total and conjugated antibody were investigated.
  • Although the total antibody assay formats gave similar results for both conjugates, the mouse pharmacokinetic profile for the anti-CD22-MCC-DM1 and MC-MMAF appeared significantly different depending on the conjugated antibody assay format.
  • Since these differences significantly impacted the PK parameters determination, we investigated the effect of the drug/antibody ratio on the total and conjugated antibody quantification using multiple assay formats.
  • Our investigations revealed the limitations of some assay formats to quantify anti-CD22-MCC-DM1 and MC-MMAF with different drug load and in the context of a heterogeneous ADC population highlight the need to carefully plan the assay strategy for the total and conjugated antibody quantification in order to accurately determine the ADC PK parameters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637680.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoconjugates; 0 / Maleimides; 0 / Oligopeptides; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / monomethylauristatin F; 14083FR882 / Maytansine
  •  go-up   go-down


31. Takimoto K, Kawamura N, Kasama T: Storage of gangliosides GM2 and fucosyl GM1 in the kidney of MCC strain of mastomys (Praomys coucha). J Biochem; 2009 Sep;146(3):439-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Storage of gangliosides GM2 and fucosyl GM1 in the kidney of MCC strain of mastomys (Praomys coucha).
  • Previously, we histochemically examined the kidney of the MCC strain of mastomys (Praomys coucha) and found the storage of gangliosides.
  • In the present studies, the lipid-bound sialic acid content of gangliosides in the MCC kidney was about 9- to 14-fold higher than that of the control (MWC strain).
  • In the MCC kidney, sialic acids of male gangliosides were composed of N-acetylneuraminic acid at 91.5%; sialic acids of female gangliosides, however, were composed almost entirely of N-glycolylneuraminic acid.
  • TLC of gangliosides showed that the MCC kidney contained four abundant gangliosides (two gangliosides each in males and females).
  • These gangliosides isolated by HPLC were identified to be GM2(NeuAc) and fucosyl GM1(NeuAc) in the male MCC kidney and GM2(NeuGc) and fucosyl GM1(NeuGc) in the female MCC kidney by secondary ion mass spectrometry, TLC/immunostaining and TLC after enzyme treatments.
  • Although the MCC kidney contained control levels of the activities of beta-N-acetylhexosaminidase, alpha-l-fucosidase, N-acetylgalactosaminyltransferase and fucosyltransferase, the activity of beta-galactosidase in the MCC kidney was increased to 400-500% of that in the MWC kidney.
  • Therefore, we discussed the possibility that in the MCC kidney, GM2 was abundantly produced by the effect of increased beta-galactosidase activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556222.001).
  • [ISSN] 1756-2651
  • [Journal-full-title] Journal of biochemistry
  • [ISO-abbreviation] J. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Neuraminic Acids; 0 / Sialic Acids; 1113-83-3 / N-glycolylneuraminic acid; 19600-01-2 / G(M2) Ganglioside; 37758-47-7 / G(M1) Ganglioside; 71812-11-8 / fucosyl GM1 ganglioside; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.- / N-Acetylgalactosaminyltransferases; EC 3.2.1.18 / Neuraminidase; EC 3.2.1.23 / beta-Galactosidase; EC 3.2.1.51 / alpha-L-Fucosidase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


32. Shimizu T, Okafuji N, Nakano K, Kurihara S, Kawakami T: Jagged1 peptide appearing in mandibular condylar cartilage development. Eur J Med Res; 2008 Jan 23;13(1):4-6
eagle-i research resources. PMID 18226990 (Special Collections) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jagged1 peptide appearing in mandibular condylar cartilage development.
  • We investigated the expression pattern of Jagged1 peptide in mandibular condylar cartilage, as a type of secondary cartilage.
  • Mandibular condyle of ddY mice were fixed from embryonic day 15 (E15) through just after birth (equivalent to E19).
  • At E15, the proliferating cells had positive products of Jagged1 in their cytoplasms and cell membrane of almost all coagulating cells.
  • At E17, cytoplasmic and membranuous reactions of Jagged1 factors appeared strongly in the cells just inside the condylar cartilage sheath.
  • At E18, Jagged1 positive products were observed in almost all cells of the layers, and they were mostly distinct in the sheath of the condyle.
  • At just after birth, Jagged1 was observed in a portion of almost all layer cells in their cytoplasm and membrane.
  • These results suggest that Jagged1 plays an essential role for mandibular condylar cartilage morphogenesis and development.
  • [MeSH-major] Calcium-Binding Proteins / metabolism. Cartilage / embryology. Intercellular Signaling Peptides and Proteins / metabolism. Mandibular Condyle / embryology. Membrane Proteins / metabolism
  • [MeSH-minor] Animals. Cell Membrane / metabolism. Chondrocytes / metabolism. Cytoplasm / metabolism. Mice. Mice, Inbred Strains. Osteogenesis / physiology. Osteopontin / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226990.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 106441-73-0 / Osteopontin; 134324-36-0 / Serrate proteins
  •  go-up   go-down


33. Handschel J, Müller D, Depprich RA, Ommerborn MA, Kübler NR, Naujoks C, Reifenberger J, Schäfer KL, Braunstein S: The new polyomavirus (MCPyV) does not affect the clinical course in MCCs. Int J Oral Maxillofac Surg; 2010 Nov;39(11):1086-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new polyomavirus (MCPyV) does not affect the clinical course in MCCs.
  • Since 2008, a new polyomavirus (MCPyV) in Merkel cell carcinomas (MCC) has been described, but little is known about its impact on the clinical course.
  • The purpose of this study was to determine the presence of MCPyV in a large sample and to correlate the results with the clinical course of the disease.
  • 57% of primary tumours and 53% of metastases were positive for LT3; the numbers for VP1 and LT1 were lower.
  • There was no correlation between the detection of MCPyV in the primary tumour and the appearance of metastases.
  • There is a striking occurrence of MCPyV in MCC, but whether it affects the clinical course remains unclear.
  • [MeSH-major] Carcinoma, Merkel Cell / virology. Polyomavirus / isolation & purification. Skin Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20678899.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


34. Li N, Wolgamot G, Argenyi Z: Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma. J Cutan Pathol; 2007 May;34(5):410-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma.
  • Although primary cutaneous neuroendocrine cell carcinoma [Merkel cell carcinoma (MCC)] may show divergent features, including microcystic ('tubuloglandular'), squamous, eccrine and rhabdomyoblastic, a diffuse microcystic pattern is exceedingly rare.
  • In this study, we present two cases of MCC with prominent microcystic features, which precluded a definitive diagnosis in the initial punch biopsy.
  • Punch biopsies from both patients revealed an infiltrating neoplasm with prominent microcystic features that mimick tubuloglandular structures, lined by hyperchromatic basaloid cells, which were strongly positive for chromogranin and BerEP4, variably positive for CK7 and CK5/6 and negative for CK20, synaptophysin, S-100, epithelial membrane antigen (EMA), gross cystic disease fluid protein-15 (GCDFP-15), estrogen/progesterone receptors (ER/PR), thyroid transcription factor 1 (TTF1) and carcinoembryonic antigen (CEA).
  • Although the lack of CK20 staining is unusual, the histologic characteristics along with the remaining immunohistochemical studies favor the diagnosis of a primary cutaneous neuroendocrine cell carcinoma over the variants of eccrine carcinoma or basal cell carcinoma with neuroendocrine differentiation.
  • Our cases illustrate that prominent microcystic features, mimicking glandular differentiation, may occur in MCC and pose a diagnostic challenge in small biopsy specimens.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Eccrine Glands / pathology. Humans. Immunohistochemistry. Male. Neck / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448197.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Spalvieri C, Brunelli F, Bachmeyer CC: Merkel cell tumour of the finger. Scand J Plast Reconstr Surg Hand Surg; 2007;41(3):149-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumour of the finger.
  • Merkel cell carcinoma (MCC) is a rare primary neuroendocrine tumour.
  • We report a case of MCC on the dorsal base of the left second finger and we discuss its treatment and prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486523.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Ibrahim B, Schmitt E, Dittrich P, Diekmann S: In silico study of kinetochore control, amplification, and inhibition effects in MCC assembly. Biosystems; 2009 Jan;95(1):35-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In silico study of kinetochore control, amplification, and inhibition effects in MCC assembly.
  • Eukaryotic cells rely on a surveillance mechanism, the "Spindle Assembly Checkpoint"SACM in order to ensure accurate chromosome segregation by preventing anaphase initiation until all chromosomes are correctly attached to the mitotic spindle.
  • In different organisms, a mitotic checkpoint complex (MCC) composed of Mad2, Bub3, BubR1/Mad3, and Cdc20 inhibits the anaphase promoting complex (APC/C) to initiate promotion into anaphase.
  • The mechanism of MCC formation and its regulation by the kinetochore are unclear.
  • Here, we constructed dynamical models of MCC formation involving different kinetochore control mechanisms including amplification as well as inhibition effects, and analysed their quantitative properties.
  • Furthermore, when introducing experimentally determined parameter values into the models analysed here, we found that effective MCC formation is not combined with complete Cdc20 sequestering.
  • Instead, the MCC might bind and completely block the APC/C.
  • The SACM might function by an MCC:APC/C complex rearrangement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675311.001).
  • [ISSN] 1872-8324
  • [Journal-full-title] Bio Systems
  • [ISO-abbreviation] BioSystems
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


37. Wang X, Feng Y, Liu J, Lee H, Li C, Li N, Ren N: Sequestration of CO2 discharged from anode by algal cathode in microbial carbon capture cells (MCCs). Biosens Bioelectron; 2010 Aug 15;25(12):2639-43
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequestration of CO2 discharged from anode by algal cathode in microbial carbon capture cells (MCCs).
  • By introducing anodic off gas into an algae grown cathode (Chlorella vulgaris), new microbial carbon capture cells (MCCs) were constructed and demonstrated here to be an effective technology for CO(2) emission reduction with simultaneous voltage output without aeration (610+/-50 mV, 1000 Omega).
  • Compared to a stable voltage of 706+/-21 mV (1000 Omega) obtained with cathodic dissolved oxygen (DO) of 6.6+/-1.0 mg/L in MCC, voltage outputs decreased from 654 to 189 mV over 70 h in the control reactor (no algae) accompanied with a decrease in DO from 7.6 to 0.9 mg/L, indicating that cathode electron acceptor was oxygen.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20547055.001).
  • [ISSN] 1873-4235
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 142M471B3J / Carbon Dioxide
  •  go-up   go-down


38. Tanaka E, Iwabuchi Y, Rego EB, Koolstra JH, Yamano E, Hasegawa T, Kawazoe A, Kawai N, Tanne K: Dynamic shear behavior of mandibular condylar cartilage is dependent on testing direction. J Biomech; 2008;41(5):1119-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic shear behavior of mandibular condylar cartilage is dependent on testing direction.
  • Little information is available on the direction-dependency of shear behavior in mandibular condylar cartilage.
  • Therefore, we tested the hypothesis that such a dependency of the dynamic shear properties is present in mandibular condylar cartilage.
  • From each of 17 condyles, two cartilage-bone plugs were dissected and tested in a simple shear sandwich configuration under a compressive strain of 10%.
  • In conclusion, the present results clearly show the direction-dependent characteristic of the mandibular condylar cartilage in dynamic shear.
  • [MeSH-major] Cartilage / physiology. Mandibular Condyle / physiology. Shear Strength

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18242620.001).
  • [ISSN] 0021-9290
  • [Journal-full-title] Journal of biomechanics
  • [ISO-abbreviation] J Biomech
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Shimizu T: Participation of Runx2 in mandibular condylar cartilage development. Eur J Med Res; 2006 Nov 30;11(11):455-61
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Participation of Runx2 in mandibular condylar cartilage development.
  • OBJECTIVE: The purpose of this study was to investigate the expression pattern of Runx2 in mandibular condylar cartilage, a type of secondary cartilage.
  • METHODS: Mandibular condyle of ddY mice were fixed from embryonic day 14 (E14) through just after birth (equivalent to E19).
  • Samples were cut into 4 micro m serial sections through the central area of the mandibular condyle at the sagittal plane.
  • RESULTS: There are no developmental features of mandibular condyle.
  • At the distal upper portion of developmental mandibular bone, mesenchymal cell proliferation and condensation without metacholomatic reaction to Toluidine blue (TB) were seen at E14.
  • At E15, mandibular condylar cartilage was clearly evident, as TB metacholomasia.
  • In IHC specimens at E14, expression of Runx2 peptide was observed in the nuclei and the cytoplasms cells of coagulating mesenchymal cells, both in the cytoplasm and nucleus.
  • After E17, Runx2 appeared in the cells of the condylar cartilage sheath.
  • CONCLUSION: These IHC and ISH results suggest that Runx2 plays an essential role for mandibular condylar cartilage development, especially that Runx2 is essential for the onset of secondary cartilage differentiation.
  • [MeSH-major] Cartilage / metabolism. Core Binding Factor Alpha 1 Subunit / metabolism. Gene Expression Regulation, Developmental. Mandibular Condyle / metabolism
  • [MeSH-minor] Animals. Cells, Cultured. Chondrocytes / metabolism. Collagen Type II / metabolism. Female. In Situ Hybridization. Mice. Osteopontin / metabolism. Pregnancy. RNA Probes. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17182356.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Collagen Type II; 0 / Core Binding Factor Alpha 1 Subunit; 0 / RNA Probes; 0 / RNA, Messenger; 0 / Runx2 protein, mouse; 106441-73-0 / Osteopontin
  •  go-up   go-down


40. Schwarz NG, Gysels M, Pell C, Gabor J, Schlie M, Issifou S, Lell B, Kremsner PG, Grobusch MP, Pool R: Reasons for non-adherence to vaccination at mother and child care clinics (MCCs) in Lambaréné, Gabon. Vaccine; 2009 Aug 27;27(39):5371-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reasons for non-adherence to vaccination at mother and child care clinics (MCCs) in Lambaréné, Gabon.
  • The aim of this paper is to explore attitudes of mothers towards childhood vaccinations and reasons for non-attendance and non-adherence to mother-child clinics (MCCs).
  • Important reasons for MCC non-attendance included distance to the MCC, transport costs, negative experiences at MCCs (such as interactions with unfriendly staff) and mothers' feeling of shame provoked by different, often poverty-associated reasons such as attending the clinic with a dirty or poorly clothed child.

  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19616497.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Jiao K, Wang MQ, Niu LN, Dai J, Yu SB, Liu XD: Mandibular condylar cartilage response to moving 2 molars in rats. Am J Orthod Dentofacial Orthop; 2010 Apr;137(4):460.e1-8; discussion 460-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mandibular condylar cartilage response to moving 2 molars in rats.
  • INTRODUCTION: The purpose of this study was to investigate the responses of mandibular condylar cartilage to moving 2 molars in different combinations.
  • Elastic rubber bands were used to move medially the maxillary left and the mandibular right first molars in experimental group I.
  • The same method was used to distally move the maxillary left and the mandibular right third molars, 2 mandibular third molars, and 2 maxillary third molars in experimental groups II, III, and IV, respectively.
  • The areas of histologic change as a percentage of total cartilage area were compared by using the Mann-Whitney U test.
  • RESULTS: Cartilage degenerative remodeling was observed in experimental groups II, III, and IV.
  • CONCLUSIONS: The mandibular condylar cartilage of female rats responded variously to different combinations of molar movement; the most obvious remodeling was observed in groups in which the maxillary left and mandibular right third molars were moved.
  • [MeSH-major] Cartilage, Articular / physiopathology. Malocclusion / physiopathology. Mandibular Condyle / physiopathology. Molar / pathology
  • [MeSH-minor] Animals. Cartilage Diseases / pathology. Cartilage Diseases / physiopathology. Case-Control Studies. Cell Proliferation. Chondrocytes / pathology. Cytoplasm / pathology. Extracellular Matrix Proteins / analysis. Female. Male. Molar, Third / pathology. Musculoskeletal Physiological Processes. Orthodontic Appliances. Proteoglycans / analysis. Random Allocation. Rats. Rats, Sprague-Dawley. Sex Factors. Tooth Movement / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Association of Orthodontists. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20362904.001).
  • [ISSN] 1097-6752
  • [Journal-full-title] American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
  • [ISO-abbreviation] Am J Orthod Dentofacial Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; 0 / Proteoglycans
  •  go-up   go-down


47. Finner H, Strassburger K: Step-up related simultaneous confidence intervals for MCC and MCB. Biom J; 2007 Feb;49(1):40-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Step-up related simultaneous confidence intervals for MCC and MCB.
  • In this article we consider (one-sided) multiple comparisons with a control (MCC) and multiple comparisons with the best (MCB) with the aim of establishing delta-equivalence to the best and derive step-up related confidence bounds by applying the projection method proposed in Finner and Strassburger (2006).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342948.001).
  • [ISSN] 0323-3847
  • [Journal-full-title] Biometrical journal. Biometrische Zeitschrift
  • [ISO-abbreviation] Biom J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Reimer JM, Enoksson M, Samollow PB, Hellman L: Extended substrate specificity of opossum chymase--implications for the origin of mast cell chymases. Mol Immunol; 2008 Apr;45(7):2116-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended substrate specificity of opossum chymase--implications for the origin of mast cell chymases.
  • Serine proteases are major granule constituents of mast cells, neutrophils, T cells and NK cells.
  • The mast cell chymase locus e.g. comprises at least one alpha-chymase, one cathepsin G, and two granzyme genes in almost all mammalian species investigated.
  • Phylogenetic analyses place one of them clearly with the alpha-chymases, whereas the other gene is equally related to cathepsin G and the granzymes.
  • To study the function of opossum chymase, and to explore the evolutionary origin of mast cell chymases, we have analyzed the cleavage specificity of this enzyme.
  • The protease was expressed in mammalian cells and the extended substrate specificity was determined using a randomized phage-displayed nonapeptide library.
  • This is in contrast to human chymase and mouse mast cell protease-4, which prefer Phe over Tyr and Trp in this position.
  • However, in most other positions this enzyme shows amino acid preferences very similar to human chymase and mouse mast cell protease-4, i.e. aliphatic amino acids in positions P4, P3, P2 and P1', and acidic amino acids (Glu and Asp) in the P2' position.
  • The overall specificity of MC chymase thereby seems to have been conserved over almost 200 million years of mammalian evolution, indicating a strong selective pressure in maintaining this specificity and an important role for these enzymes in mast cell biology.
  • [MeSH-major] Chymases / metabolism. Mast Cells / enzymology. Opossums / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022236.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR014214
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 0 / DNA, Complementary; 0 / Recombinant Proteins; EC 3.4.21.39 / Chymases
  •  go-up   go-down


49. Gallwitz M, Reimer JM, Hellman L: Expansion of the mast cell chymase locus over the past 200 million years of mammalian evolution. Immunogenetics; 2006 Aug;58(8):655-69
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expansion of the mast cell chymase locus over the past 200 million years of mammalian evolution.
  • The acidic granules of natural killer (NK) cells, T cells, mast cells, and neutrophils store large amounts of serine proteases.
  • Functionally, these proteases are involved, e.g., in the induction of apoptosis, the recruitment of inflammatory cells, and the remodeling of extra-cellular matrix.
  • Among the granule proteases are the phylogenetically related mast cell chymases, neutrophil cathepsin G, and T-cell granzymes (Gzm B to H and Gzm N), which share the characteristic absence of a Cys(191)-Cys(220) bridge.
  • The genes of these proteases are clustered in one locus, the mast cell chymase locus, in all previously investigated mammals.
  • In this paper, we present a detailed analysis of the chymase locus in cattle (Bos taurus) and opossum (Monodelphis domestica).
  • The gained information delineates the evolution of the chymase locus over more than 200 million years.
  • Surprisingly, the cattle chymase locus contains two alpha-chymase and two cathepsin G genes where all other studied chymase loci have single genes.
  • Moreover, the cattle locus holds at least four genes for duodenases, which are not found in other chymase loci.
  • In opossum, on the other hand, only two chymase locus-related genes have been identified.
  • Phylogenetic analyses place one of the opossum genes firmly with mast cell alpha-chymases, which indicates that the alpha-chymase had already evolved as a separate, clearly identifiable gene before the separation of marsupials and placental mammals.
  • In platypus, only one chymase locus-like sequence could be identified.
  • This previously published "granzyme" does not cluster clearly with any of the chymase locus gene families, but shares the absence of the Cys(191)-Cys(220) bridge with the other chymase locus proteases.
  • These findings indicate that all chymase locus genes are derived from a single ancestor that was present more than 200 million years ago.
  • [MeSH-major] Evolution, Molecular. Genetic Variation. Mast Cells / enzymology. Serine Endopeptidases / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Cathepsin G. Cathepsins / genetics. Cattle. Chromosome Mapping. Chymases. Dogs. Humans. Mice. Molecular Sequence Data. Opossums. Phylogeny. Rats. Sequence Homology, Amino Acid. Sheep

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1998 Jul 28;1386(1):189-98 [9675278.001]
  • [Cites] Genetics. 2000 May;155(1):431-49 [10790415.001]
  • [Cites] Mol Cell. 2003 Aug;12(2):343-54 [14536074.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):423-31 [12900518.001]
  • [Cites] Immunogenetics. 2000 Nov;52(1-2):19-28 [11132153.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):493-521 [15057822.001]
  • [Cites] Proteins. 2000 Oct 1;41(1):8-16 [10944388.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 14;1480(1-2):245-57 [10899625.001]
  • [Cites] Biochem J. 1997 Feb 1;321 ( Pt 3):665-70 [9032451.001]
  • [Cites] Eur J Biochem. 2002 Dec;269(23):5921-30 [12444981.001]
  • [Cites] J Recept Signal Transduct Res. 2005;25(1):35-44 [15960393.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):98-103 [1985927.001]
  • [Cites] J Mol Evol. 2003 Feb;56(2):234-42 [12574869.001]
  • [Cites] Eur J Biochem. 1995 Feb 1;227(3):873-9 [7867649.001]
  • [Cites] Biochemistry (Mosc). 2003 Mar;68(3):309-16 [12733972.001]
  • [Cites] Nat Struct Biol. 1994 Jun;1(6):364-7 [7664048.001]
  • [Cites] Atherosclerosis. 2001 Mar;155(1):87-97 [11223430.001]
  • [Cites] Mol Biol Evol. 2001 May;18(5):777-91 [11319262.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9017-21 [9256427.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9291-6 [15615702.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3354-9 [15718282.001]
  • [Cites] Immunogenetics. 2003 Jul;55(4):193-202 [12756505.001]
  • [Cites] Dev Comp Immunol. 2006;30(10):901-18 [16413608.001]
  • [Cites] Mol Phylogenet Evol. 2003 Aug;28(2):360-85 [12878472.001]
  • [Cites] J Mol Evol. 1996 Mar;42(3):337-49 [8661995.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39625-31 [12900423.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Protein Sci. 1995 Mar;4(3):337-60 [7795518.001]
  • [Cites] J Mol Evol. 2000 Jun;50(6):569-78 [10835487.001]
  • [Cites] J Immunol. 1997 Aug 15;159(4):1987-92 [9257865.001]
  • [Cites] Genome Res. 2004 Apr;14(4):609-22 [15060002.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):801-9 [9677343.001]
  • [Cites] Genome Res. 2003 May;13(5):813-20 [12727901.001]
  • [Cites] Genome Res. 2004 Apr;14(4):574-9 [15059998.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34517-24 [12815038.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):762-5 [10966646.001]
  • [Cites] Eur J Biochem. 1997 Oct 15;249(2):612-21 [9370374.001]
  • [Cites] Clin Chim Acta. 2004 Sep;347(1-2):223-5 [15313162.001]
  • [Cites] Mol Immunol. 2002 Sep;38(16-18):1353-7 [12217407.001]
  • [Cites] Nature. 1998 Apr 30;392(6679):917-20 [9582070.001]
  • [Cites] Immunogenetics. 2006 Aug;58(8):641-54 [16807746.001]
  • [Cites] Trends Genet. 2002 Oct;18(10):517-21 [12350341.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25628-35 [9325284.001]
  • [Cites] Biochemistry. 1988 Oct 18;27(21):8097-105 [3233198.001]
  • [Cites] Genome Res. 2004 Apr;14(4):539-48 [15059994.001]
  • [Cites] J Immunol. 1987 Apr 15;138(8):2611-5 [3549903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1056-61 [12552136.001]
  • [Cites] EMBO J. 1996 Oct 15;15(20):5481-91 [8896442.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):1022-33 [9541598.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30468-73 [10521426.001]
  • [Cites] Mol Biol Evol. 2006 Mar;23(3):587-97 [16291999.001]
  • (PMID = 16807745.001).
  • [ISSN] 0093-7711
  • [Journal-full-title] Immunogenetics
  • [ISO-abbreviation] Immunogenetics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.- / Cathepsins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / duodenase; EC 3.4.21.20 / CTSG protein, human; EC 3.4.21.20 / Cathepsin G; EC 3.4.21.20 / Ctsg protein, mouse; EC 3.4.21.20 / Ctsg protein, rat; EC 3.4.21.39 / Chymases
  •  go-up   go-down


50. Yu SB, Wang MQ, Li YQ, Lv X, Jiang Y, Dong GY, Ma ZF: The effects of age and sex on the expression of oestrogen and its receptors in rat mandibular condylar cartilages. Arch Oral Biol; 2009 May;54(5):479-85
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of age and sex on the expression of oestrogen and its receptors in rat mandibular condylar cartilages.
  • The purpose of this study was to investigate the expression of oestrogen and oestrogen receptors in mandibular condylar cartilages in male and female Sprague-Dawley rats at different ages.
  • The expression of oestradiol, ERalpha and ERbeta was detected in mandibular condylar cartilages by the method of immunohistochemistry, and enzyme-linked immunosorbent assay or western blot.
  • RESULTS: Oestradiol and ERs immunoreactivity were obvious in mandibular condylar cartilages of SD rats.
  • CONCLUSIONS: The results that oestradiol, ERalpha and ERbeta are co-expressed in rat mandibular condylar cartilage, indicate that mandibular condylar cartilage is a target for oestrogen.
  • [MeSH-major] Cartilage, Articular / cytology. Estrogens / analysis. Mandibular Condyle / cytology. Receptors, Estrogen / analysis
  • [MeSH-minor] Age Factors. Animals. Blotting, Western. Cell Proliferation. Chondrocytes / cytology. Enzyme-Linked Immunosorbent Assay. Estradiol / analysis. Estrogen Receptor alpha / analysis. Estrogen Receptor beta / analysis. Female. Hypertrophy. Immunohistochemistry. Male. Rats. Rats, Sprague-Dawley. Receptors, Estradiol / analysis. Sex Factors. Temporal Bone / cytology. Temporomandibular Joint Disc / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264293.001).
  • [ISSN] 1879-1506
  • [Journal-full-title] Archives of oral biology
  • [ISO-abbreviation] Arch. Oral Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Receptors, Estradiol; 0 / Receptors, Estrogen; 4TI98Z838E / Estradiol
  •  go-up   go-down


51. Gass JK, Chan SK, Rytina E, Greenberg DC, Burrows NP: Multiple primary malignancies in patients with Merkel cell carcinoma. J Eur Acad Dermatol Venereol; 2010 May;24(5):601-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary malignancies in patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare malignant cutaneous tumour, the incidence of which is increasing.
  • OBJECTIVES: We report the rate and nature of multiple malignancies in patients with MCC treated over a 10 year period in Addenbrooke's Hospital in Cambridge, United Kingdom, as well as the temporal relationship of these additional malignancies to the diagnosis of MCC.
  • RESULTS: The 27 patients had an approximately equal sex incidence with a median age at diagnosis of 79 years.
  • Seventy percent (n=19) of patients had a second primary malignant tumour; and 7 of these patients had two or more tumours in addition to the MCC.
  • Eighteen patients had additional cutaneous malignancies: melanoma, squamous cell carcinoma and basal cell carcinoma, and 8 patients presented non-cutaneous malignancy including colorectal, haematological and breast tumours.
  • Of the 28 additional tumours in our patients, half were diagnosed prior to presentation of MCC, 32% within 6 months of diagnosis, and 18% between 6 months and 3 years after diagnosis.
  • CONCLUSIONS: Our figures reflect a higher incidence of multiple malignancies in those with Merkel cell tumour than has previously been reported.
  • [MeSH-major] Carcinoma, Merkel Cell / complications. Neoplasms, Multiple Primary / complications. Skin Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900177.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


52. Arnaud C, Sebbagh M, Nola S, Audebert S, Bidaut G, Hermant A, Gayet O, Dusetti NJ, Ollendorff V, Santoni MJ, Borg JP, Lécine P: MCC, a new interacting protein for Scrib, is required for cell migration in epithelial cells. FEBS Lett; 2009 Jul 21;583(14):2326-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MCC, a new interacting protein for Scrib, is required for cell migration in epithelial cells.
  • To further characterize the molecular events supporting the tumor suppressor activity of Scrib in mammals, we aim to identify new binding partners.
  • We isolated MCC, a recently identified binding partner for beta-catenin, as a new interacting protein for Scrib.
  • MCC interacts with both Scrib and the NHERF1/NHERF2/Ezrin complex in a PDZ-dependent manner.
  • In T47D cells, MCC and Scrib proteins colocalize at the cell membrane and reduced expression of MCC results in impaired cell migration.
  • By contrast to Scrib, MCC inhibits cell directed migration independently of Rac1, Cdc42 and PAK activation.
  • Altogether, these results identify MCC as a potential scaffold protein regulating cell movement and able to bind Scrib, beta-catenin and NHERF1/2.
  • [MeSH-major] Cell Movement / physiology. Epithelial Cells / physiology. Membrane Proteins / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Cell Line. Enzyme Activation. Humans. Phosphoproteins / genetics. Phosphoproteins / metabolism. Protein Binding. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Sodium-Hydrogen Antiporter / genetics. Sodium-Hydrogen Antiporter / metabolism. beta Catenin / metabolism. cdc42 GTP-Binding Protein / metabolism. rac1 GTP-Binding Protein / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19555689.001).
  • [ISSN] 1873-3468
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / Recombinant Fusion Proteins; 0 / SCRIB protein, human; 0 / Sodium-Hydrogen Antiporter; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / sodium-hydrogen exchanger regulatory factor; 137764-10-4 / MCC protein, human; EC 3.6.5.2 / cdc42 GTP-Binding Protein; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


53. Howard MA, Neau SH, Sack MJ: PEO and MPEG in high drug load extruded and spheronized beads that are devoid of MCC. Int J Pharm; 2006 Jan 3;307(1):66-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEO and MPEG in high drug load extruded and spheronized beads that are devoid of MCC.
  • A means to produce extruded-spheronized beads, devoid of microcrystalline cellulose (MCC) and with a high drug load (greater than 80%, w/w), is presented.
  • The success of this approach has important implications in cases where high drug load beads are desired, but where MCC cannot be used due to chemical incompatibility or where complete release cannot be achieved with MCC-containing beads.

  • Hazardous Substances Data Bank. (L)-EPHEDRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253448.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / microcrystalline cellulose; 30IQX730WE / Polyethylene Glycols; 9004-34-6 / Cellulose; 9004-74-4 / monomethoxypolyethylene glycol; GN83C131XS / Ephedrine
  •  go-up   go-down


54. Pilloni L, Manieli C, Senes G, Ribuffo D, Faa G: Merkel cell carcinoma with an unusual immunohistochemical profile. Eur J Histochem; 2009 Oct-Dec;53(4):275-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma with an unusual immunohistochemical profile.
  • The clinical and morphological picture of Merkel cell carcinoma (MCC) may be rather challenging; therefore, the immunohistochemical profile plays a relevant role in confirming the microscopic diagnosis.
  • A panel of antibodies including cytokeratins 20, 7 and epithelial membrane antigen, and neuron specific enolase is used in confirming the morphological diagnosis of MCC.
  • The majority of MCCs express CK20 and are CK7-negative.
  • Herein, we present a case of primary cutaneous neuroendocrine carcinoma with an atypical immunohistochemical pattern.
  • The skin tumor was excided, formalin-fixed and paraffin embedded.
  • Tissue sections were immunostained with a panel of antibodies routinely utilized in complex primary skin tumors for evidencing epithelial and neuroendocrine differentiation of tumor cells.
  • The neuroendocrine differentiation of tumor cells was evidenced by their immunoreactivity for synaptophysin, chromogranin A and neuron-specific enolase.
  • Tumor cells also showed diffuse cytoplasmic staining for CK7.
  • Our data, together with previous rare reports of CK20-/CK7+ MCCs, lay stress on the importance of routinely utilizing a panel of antibodies in the differential diagnosis of complex primary carcinomas of the skin and may have important implications in expanding the differential diagnosis of skin tumors.
  • In particular, caution should be taken in excluding the diagnosis of MCC only on the basis of the absence of reactivity of tumor cells for CK20, favouring the wrong diagnosis of less aggressive skin tumors.
  • [MeSH-major] Carcinoma, Merkel Cell. Skin Neoplasms
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20007099.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


55. Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S: Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm; 2008 Nov 3;363(1-2):139-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
  • In this study, the nanoparticulate systems were prepared by using differently charged chitosan derivatives, N-trimethyl chitosan (TMC, polycationic), and mono-N-carboxymethyl chitosan (MCC, polyampholytic) for mucosal immunisation.
  • The cytotoxicity studies (MTT assay) on Chinese hamster ovary (CHO-K1) cell lines showed that cell viability was in the order of MCC, chitosan and TMC.
  • Nanoparticles with high loading efficacy (>90% m/m), particle size within the range of 40-400nm, with a negative surface charge for MCC and positive surface charge for TMC and chitosan were obtained.
  • The effective uptake of the FITC-BSA loaded nanoparticles into the cells was demonstrated by cellular uptake studies using J774A.1 cells.
  • Chitosan and TMC nanoparticles which have positively charged surfaces induced higher serum IgG titres when compared to those prepared with MCC which are negatively charged and smaller in size.
  • [MeSH-minor] Administration, Intranasal. Animals. CHO Cells. Cell Survival / drug effects. Chemistry, Pharmaceutical. Cricetinae. Cricetulus. Drug Compounding. Fluorescein-5-isothiocyanate / analogs & derivatives. Fluorescein-5-isothiocyanate / metabolism. Immunity, Mucosal / drug effects. Immunoglobulin G / blood. Injections, Subcutaneous. Macrophages / metabolism. Mice. Mice, Inbred C57BL. Serum Albumin, Bovine / metabolism

  • MedlinePlus Health Information. consumer health - Immunization.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18662762.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Drug Carriers; 0 / Immunoglobulin G; 0 / N-trimethyl chitosan chloride; 0 / Serum Albumin, Bovine; 0 / Tetanus Toxoid; 0 / Vaccines; 0 / fluorescein isothiocyanate bovine serum albumin; 0 / mono-N-carboxymethylchitosan; 9012-76-4 / Chitosan; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


56. Koljonen V, Kukko H, Tukiainen E, Böhling T, Sankila R, Pukkala E, Sihto H, Joensuu H, Kyllönen L, Mäkisalo H: Incidence of Merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant; 2009 Oct;24(10):3231-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of Merkel cell carcinoma in renal transplant recipients.
  • BACKGROUND: The risk factors for Merkel cell carcinoma (MCC), a rare type of skin cancer, are poorly understood.
  • Some evidence suggests that MCC is more common in individuals with abnormal immune function resulting from viral infection, autoimmune disease or organ trans- plantation.
  • METHODS: The national Renal Transplant Registry and the Finnish Cancer Registry data were searched for recipients of a renal transplant who were diagnosed with MCC.
  • The MCC diagnoses were confirmed using immunohistochemistry.
  • RESULTS: Three cases of MCC were detected among 4200 individuals who underwent renal transplantation from 1967 to 2005 [expected number 0.05, standardized incidence ratio (SIR) 66, 95% CI 14-194, P <0.001].
  • The latency period between the transplant and detection of MCC ranged from 6 to 19 years.
  • In all three cases, the cause of transplantation was an autoimmune disease.
  • All three died from aggressive MCC with a survival time ranging from 0.5 to 2.1 years.
  • CONCLUSIONS: The results indicate that the risk of MCC is greatly increased among subjects who have undergone renal transplantation.
  • The course of the disease appears aggressive in this patient population.
  • The physicians who treat recipients of a kidney transplant should be aware of the substantially increased risk of MCC.
  • [MeSH-major] Carcinoma, Merkel Cell / epidemiology. Kidney Transplantation / adverse effects. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Humans. Incidence. Male. Middle Aged

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586970.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Fernández-Figueras MT, Puig L, Musulen E, Gilaberte M, Ferrándiz C, Lerma E, Ariza A: Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. Histopathology; 2005 Jun;46(6):614-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma.
  • AIMS: To compare the immunohistochemical expression of prognostic markers p27(Kip1), p45(Skp2) and Ki67 in Merkel cell carcinoma (primary neuroendocrine carcinoma of the skin, MCC), small cell neuroendocrine carcinoma of lung and urinary bladder (SNC), and cutaneous squamous cell carcinoma (SCC).
  • METHODS AND RESULTS: Immunohistochemistry was performed using antibodies directed against p27(Kip1), p45(Skp2) and Ki67 on 72 tumour cases: 24 MCC, 25 SCC, and 23 SNC (15 from the lung and eight from the urinary bladder).
  • Percentages of positive cells were determined for each marker and statistically analysed.
  • Expression profiles on MCC and SCC were significantly different for all three markers.
  • MCC and SNC exhibited significant similarities in their p27(Kip1) and p45(Skp2) expression profiles.
  • In contrast, MCC and SNC differed significantly in their Ki67 proliferation indices, which were much higher in SNC.
  • Additionally, MCC cases showed an association between increased proliferation indices and the appearance of local recurrence(s) and/or metastases.
  • CONCLUSION: The immunohistochemical profile of MCC differs from that of SCC, in spite of their common oncogenesis and the supposed metaplastic origin of MCC, and resembles that of SNC, except for Ki67 levels, which were higher in the latter (characterized by greater biological aggressiveness).
  • High levels of Ki67 also appear to be a prognostic factor in MCC.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Merkel Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910592.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1B protein, human; 0 / Carrier Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / S-Phase Kinase-Associated Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


58. Carvalho J, Fullen D, Lowe L, Su L, Ma L: Comparison of CD23 staining patterns in Merkel cell carcinoma and non-cutaneous small cell carcinoma. J Cutan Pathol; 2009 Feb;36(2):206-10
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of CD23 staining patterns in Merkel cell carcinoma and non-cutaneous small cell carcinoma.
  • BACKGROUND: During our daily practice, we observed that cluster designation 23 (CD23) (clone BU38) labels Merkel cells in normal skin.
  • In this study, we examined the expression of CD23 in Merkel cell carcinoma (MCC) and assessed its usefulness in distinguishing MCC from non-cutaneous small cell carcinoma (SMCC).
  • METHODS: Immunohistochemical staining of CD23 was performed on a total of 33 MCCs, 22 SMCCs and 5 carcinoid tumors.
  • RESULTS: CD23 reactivity was present in 32 of 33 (97%) MCCs, 18 of 22 (82%) SMCCs and 5 of 5 (100%) carcinoid tumors.
  • In MCC, 19 cases (59%) showed a predominance of perinuclear dot-like staining similar to cytokeratin 20, 3 (9%) showed mostly cytoplasmic staining and 10 (31%) displayed a combination of perinuclear dot-like and cytoplasmic staining.
  • In contrast, all CD23-positive SMCCs and carcinoid tumors showed a diffuse cytoplasmic staining.
  • There was a significant difference in the CD23 staining patterns between MCC and SMCC (p < 0.0001).
  • CONCLUSION: CD23 is expressed in the majority of MCC, SMCC and carcinoid tumor irrespective of clinical outcome.
  • The distinct punctate CD23 staining for MCC may be helpful in differentiating it from SMCC.
  • To our knowledge, this is the first study to show the expression of CD23 in neuroendocrine tumors.
  • [MeSH-major] Carcinoid Tumor / metabolism. Carcinoma, Merkel Cell / metabolism. Carcinoma, Small Cell / metabolism. Gene Expression Regulation, Neoplastic. Receptors, IgE / biosynthesis. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616759.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, IgE
  •  go-up   go-down


59. Faye N, Lafitte F, Martin Duverneuil N, Guillevin R, Teriitehau C, Cordoliani YS, Chiras J: Merkel cell tumor: report of two cases and review of the literature. J Neuroradiol; 2005 Mar;32(2):138-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumor: report of two cases and review of the literature.
  • The "Merkel cell carcinoma" is a rare tumor usually occuring in the sun-exposed skin.
  • Descriptions of the imaging features of this type of tumor are rare.
  • We present two cases of Merkel cell carcinoma localized to the head region.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Merkel Cell / secondary. Head and Neck Neoplasms / pathology. Scalp. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984406.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


60. Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, de Garavilla L, Hall J, Minor LK, Wang Y, Corcoran TW, Di Cera E, Cantwell AM, Savvides SN, Damiano BP, Maryanoff BE: Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem; 2007 Apr 19;50(8):1727-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.
  • A series of beta-carboxamido-phosphon(in)ic acids (2) was identified as a new structural motif for obtaining potent inhibitors of human mast cell chymase.
  • An X-ray structure for 5f.chymase revealed key interactions within the enzyme active site.
  • Compound 5f was selective for inhibiting chymase versus eight serine proteases.
  • [MeSH-major] Amides / chemical synthesis. Anti-Inflammatory Agents, Non-Steroidal / chemical synthesis. Chymases / antagonists & inhibitors. Mast Cells / enzymology. Organophosphonates / chemical synthesis. Phosphinic Acids / chemical synthesis

  • Guide to Pharmacology. gene/protein/disease-specific - chymase 1, mast cell - data and references .
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361995.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Naphthalenes; 0 / Organophosphonates; 0 / Phosphinic Acids; EC 3.4.- / Cathepsins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.20 / CTSG protein, human; EC 3.4.21.20 / Cathepsin G; EC 3.4.21.20 / Ctsg protein, rat; EC 3.4.21.39 / Chymases
  •  go-up   go-down


61. McNiff JM, Cowper SE, Lazova R, Subtil A, Glusac EJ: CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: magic bullet, diagnostic pitfall, or both? J Cutan Pathol; 2005 Sep;32(8):541-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: magic bullet, diagnostic pitfall, or both?
  • BACKGROUND: Antibodies to CD56 label natural killer (NK) cell lymphomas and neuroendocrine tumors such as Merkel cell carcinoma (MCC).
  • In MCC altered by crush artifact or obscured by lymphocytes, the histologic features coupled with CD56 positivity can lead to an erroneous impression of NK-cell lymphoma.
  • METHODS: Eighteen cases of MCC were stained for CD56, CK20, MNF116, and pankeratin.
  • The results were compared to histologic features and CD56 staining pattern of three NK-cell lymphomas.
  • RESULTS: Three of 18 cases of MCC histologically resembled lymphoma, and CD56 positivity with CD3 and CD20 negativity initially raised the possibility of NK-cell lymphoma.
  • Two additional cases were obscured by dense inflammation, again suggesting the diagnosis of lymphoma.
  • Seventeen of 18 MCC labeled for CD56 and an equal number stained for CK20.
  • All MCC tested were positive for CAM5.2 (14/14) and MNF116 (17/17).
  • Antibodies to pankeratin labeled only one of 18 MCC.
  • Staining for CD56 was stronger in MCC than NK-cell lymphomas.
  • CONCLUSIONS: CD56 is a sensitive marker for MCC as well as for NK-cell lymphoma, but is not specific.
  • Importantly, CD56 positivity in crushed or inflamed biopsies of MCC may lead to an erroneous impression of NK lymphoma.
  • CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: Magic bullet, diagnostic pitfall, or both?
  • [MeSH-major] Antigens, CD56 / metabolism. Carcinoma, Merkel Cell / metabolism. Killer Cells, Natural. Lymphoma, Non-Hodgkin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115052.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Ebihara N, Funaki T, Murakami A, Takai S, Miyazaki M: Mast cell chymase decreases the barrier function and inhibits the migration of corneal epithelial cells. Curr Eye Res; 2005 Dec;30(12):1061-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell chymase decreases the barrier function and inhibits the migration of corneal epithelial cells.
  • PURPOSE: We investigated the in vitro effects of human mast cell chymase on corneal epithelial cells.
  • METHODS: Human corneal epithelial cells were incubated with human chymase at activity levels that were likely to exist in the tears of patients with vernal keratoconjunctivitis.
  • RESULTS: Incubation of chymase resulted in a decrease of barrier function of corneal epithelium.
  • Occludin protein was cleaved by chymase.
  • In the wound assay, incubation with chymase resulted in an inhibition of cell migration.
  • CONCLUSION: Human chymase causes the proteolysis of occludin and fibronectin, resulting in a decrease of barrier function and inhibition of the migration of corneal epithelial cells.
  • [MeSH-major] Cell Movement / drug effects. Epithelium, Corneal / drug effects. Mast Cells / enzymology. Serine Endopeptidases / pharmacology
  • [MeSH-minor] Blotting, Western. Cell Line, Transformed. Cell Membrane Permeability / drug effects. Cell Survival / drug effects. Cell Transformation, Viral. Chymases. Electric Impedance. Fibronectins / metabolism. Fluorescent Antibody Technique, Indirect. Humans. Membrane Proteins / metabolism. Occludin. Simian virus 40 / physiology. Wound Healing / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354619.001).
  • [ISSN] 0271-3683
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.39 / Chymases
  •  go-up   go-down


63. Dini L, Heintze C, Welke J, Stein T, Rufer V, Braun V: [Are there any differences in guideline adherence to pharmacotherapy of heart failure between individual GP practices and Medical Care Centres (MCCs)?]. Z Evid Fortbild Qual Gesundhwes; 2010;104(2):113-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Are there any differences in guideline adherence to pharmacotherapy of heart failure between individual GP practices and Medical Care Centres (MCCs)?].
  • [Transliterated title] Leitliniengerechte Pharmakotherapie bei herzinsuffizienten Patienten--Gibt es Unterschiede der Behandlung durch Hausärzte in Einzelpraxen und in Medizinischen Versorgungszentren?
  • Patients with this common disease are primarily treated by general practitioners (GPs).
  • Ambulatory care in Germany is changing; new structures for medical care (Medical Care Centres) have been registered since 2003.
  • It was of interest to evaluate medical procedures of these new structures and compare them to the one applied in traditional single practices.
  • Over a period of eight months medical pharmacotherapy in individual practices and a Medical Care Centre (MCC) was compared.
  • To ensure comparability in both settings GPs treating randomly selected patients were asked to recruit patients with heart failure, encode their NYHA class and conduct echocardiography to verify the diagnosis.
  • RESULTS: 241 heart failure patients were enrolled by general practitioners (137 in individual practices and 104 in MCCs).
  • GPs working in MCCs performed more diagnostic echocardiographies than physicians in individual practices.
  • There were only minor differences in drug prescription between the 11 GPs from single practices and the 12 GPs working in an MCC.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441018.001).
  • [ISSN] 1865-9217
  • [Journal-full-title] Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
  • [ISO-abbreviation] Z Evid Fortbild Qual Gesundhwes
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Diuretics; 0 / Mineralocorticoid Receptor Antagonists
  •  go-up   go-down


64. Friebel D, von der Hagen M, Baumgartner ER, Fowler B, Hahn G, Feyh P, Heubner G, Baumgartner MR, Hoffmann GF: The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin. Neuropediatrics; 2006 Apr;37(2):72-8
Hazardous Substances Data Bank. BIOTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin.
  • 3-Methylcrotonylglycinuria is an inborn error of leucine catabolism with an autosomal recessive pattern of inheritance that results from a deficiency of 3-methylcrotonyl-CoA carboxylase (MCC).
  • Urine analysis at the age of two years revealed massive 3-methylcrotonylglycinuria and 3-hydroxyisovaleric aciduria suggesting MCC deficiency.
  • Biochemical findings showed partial MCC deficiency in cultured fibroblasts.
  • This is the first patient with MCC deficiency caused by a heterozygote mutation and who demonstrated a substantial and sustained clinical and biochemical response to therapeutic doses of biotin.
  • Sadly, this patient again also demonstrates that the main determinant of the outcome of even easily treatable metabolic diseases is timely diagnosis.

  • Genetic Alliance. consumer health - BabyFirstTest - 3-Methylcrotonyl-CoA Carboxylase Deficiency.
  • MedlinePlus Health Information. consumer health - B Vitamins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773504.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 12001-76-2 / Vitamin B Complex; 6SO6U10H04 / Biotin; EC 6.4.- / Carbon-Carbon Ligases; EC 6.4.1.4 / methylcrotonoyl-CoA carboxylase
  •  go-up   go-down


65. Laude HC, Jonchère B, Maubec E, Carlotti A, Marinho E, Couturaud B, Peter M, Sastre-Garau X, Avril MF, Dupin N, Rozenberg F: Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. PLoS Pathog; 2010;6(8):e1001076
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma.
  • Merkel Cell Polyomavirus (MCPyV) is associated with Merkel Cell carcinoma (MCC), a rare, aggressive skin cancer with neuroendocrine features.
  • The causal role of MCPyV is highly suggested by monoclonal integration of its genome and expression of the viral large T (LT) antigen in MCC cells.
  • We investigated and characterized MCPyV molecular features in MCC, respiratory, urine and blood samples from 33 patients by quantitative PCR, sequencing and detection of integrated viral DNA.
  • We examined associations between either MCPyV viral load in primary MCC or MCPyV DNAemia and survival.
  • Patients with MCC containing more than 1 viral genome copy per cell had a longer period in complete remission than patients with less than 1 copy per cell (34 vs 10 months, P = 0.037).
  • Peripheral blood mononuclear cells (PBMC) contained MCPyV more frequently in patients sampled with disease than in patients in complete remission (60% vs 11%, P = 0.00083).
  • Sequencing of viral DNA from MCC and non MCC samples characterized common single nucleotide polymorphisms defining 8 patient specific strains.
  • However, specific molecular signatures truncating MCPyV LT were observed in 8/12 MCC cases but not in respiratory and urinary samples from 15 patients.
  • New integration sites were identified in 4 MCC cases.
  • Finally, mutated-integrated forms of MCPyV were detected in PBMC of two patients with disseminated MCC disease, indicating circulation of metastatic cells.
  • We conclude that MCPyV molecular features in primary MCC tumour and PBMC may help to predict the course of the disease.
  • [MeSH-major] Carcinoma, Merkel Cell / virology. Leukocytes, Mononuclear / virology. Polyomavirus Infections / genetics. Skin Neoplasms / virology. Tumor Virus Infections / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / analysis. DNA, Viral / genetics. Female. History, 18th Century. Humans. Immunoblotting. Male. Middle Aged. Neoplasm Staging. Polymorphism, Single Nucleotide. Polyomavirus / genetics. Proportional Hazards Models. Reverse Transcriptase Polymerase Chain Reaction


66. Gambichler T, Breininger A, Rotterdam S, Altmeyer P, Stücker M, Kreuter A: Expression of minichromosome maintenance proteins in Merkel cell carcinoma. J Eur Acad Dermatol Venereol; 2009 Oct;23(10):1184-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of minichromosome maintenance proteins in Merkel cell carcinoma.
  • OBJECTIVE: Minichromosome maintenance (MCM) nuclear proteins have barely been employed in the diagnosis of skin malignancies.
  • We aimed to assess whether MCM immunohistochemistry can be utilized to examine tumour proliferation in Merkel cell carcinoma (MCC).
  • METHODS: In this pilot study, we studied skin specimens of eight patients with MCC.
  • As a control, eight patients with cutaneous malignant melanoma (MM) were included.
  • RESULTS: Protein expression of MCM4 (66.0 +/- 26.5% vs. 33.9 +/- 22.4%; P = 0.017), MCM6 (70.9 +/- 11.9 vs. 31.7 +/- 22.7; P = 0.0031), and MCM7 (76.5 +/- 16.4% vs. 34.9 +/- 25.5%; P = 0.0013) was significantly increased in tumour cells of MCC when compared to tumour cells of MM.
  • Ki-67 immunoreactivity was also significantly higher in MCC than in MM (28.7 +/- 7.9 vs. 11.0 +/- 9.2; P = 0.0012).
  • Immunolabelling of p53 (68.6 +/- 26.2 vs. 58.4 +/- 28.8; P = 0.46) and p21 (40.1 +/- 38.8 vs. 25.8 +/- 16.1; P = 0.35) was relatively high but not significantly increased in MCC when compared to MM.
  • CONCLUSION: Our preliminary data indicate that MCM immunohistochemistry may be a useful tool for the determination of tumour cell proliferation in MCC.
  • [MeSH-major] Carcinoma, Merkel Cell / genetics. Chromosomes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453809.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


67. Jiao K, Wang MQ, Niu LN, Dai J, Yu SB, Liu XD, Wang GW: Death and proliferation of chondrocytes in the degraded mandibular condylar cartilage of rats induced by experimentally created disordered occlusion. Apoptosis; 2009 Jan;14(1):22-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death and proliferation of chondrocytes in the degraded mandibular condylar cartilage of rats induced by experimentally created disordered occlusion.
  • OBJECTIVE: To investigate the effect of experimentally created disordered occlusion (ECDO) on cell death and proliferation in rat mandibular condylar cartilage.
  • RESULTS: Time- and sex-related progressive histologic degradation was observed in the condylar cartilage of ECDO rats, accompanied with diminished chondrocyte proliferation in the female 12-week ECDO subgroup (P < 0.05).
  • CONCLUSION: ECDO induces degradation in the rat condylar cartilage accompanied by an increase in chondrocyte death.
  • [MeSH-major] Apoptosis. Cartilage / metabolism. Chondrocytes / chemistry. Mandibular Condyle / metabolism
  • [MeSH-minor] Animals. Cell Death. Cell Proliferation. Female. Immunohistochemistry. In Situ Nick-End Labeling. Male. Osteoarthritis / pathology. Rats. Rats, Sprague-Dawley. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052875.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Bowers JW, Schlauder SM, Calder KB, Morgan MB: Acetylcholine receptor expression in Merkel cell carcinoma. Am J Dermatopathol; 2008 Aug;30(4):340-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acetylcholine receptor expression in Merkel cell carcinoma.
  • These receptors are critical for migration of neurocrest-derived cells to their corresponding tissues during development.
  • Recent reports demonstrate neurocrest-derived melanoma and numerous non-Merkel cell neuroendocrine tumors express both muscarinic and nicotinic receptors.
  • In light of the controversy surrounding the origin and pathogenesis of Merkel cell carcinoma (MCC), we investigated the immunohistochemical expression of both mAChR and nAChR in MCC.
  • Fifteen cases of primary non-metastatic cutaneous MCC archived at a large veterans' hospital and tertiary referral dermatopathology service were retrieved by computer-assisted search.
  • Fifteen cases of primary cutaneous MCC were diffusely positive for M3 and M5 mAChR staining.
  • Despite the limited number of cases, MCC appears to uniformly express M3 and M5 receptors.
  • These receptors have been linked to cell proliferation and migration which may confer a potential therapeutic target.
  • [MeSH-major] Carcinoma, Merkel Cell / metabolism. Receptors, Muscarinic / biosynthesis. Receptors, Nicotinic / biosynthesis. Skin Neoplasms / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645305.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Muscarinic; 0 / Receptors, Nicotinic
  •  go-up   go-down


69. Gallwitz M, Hellman L: Rapid lineage-specific diversification of the mast cell chymase locus during mammalian evolution. Immunogenetics; 2006 Aug;58(8):641-54
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid lineage-specific diversification of the mast cell chymase locus during mammalian evolution.
  • Serine proteases constitute the major protein granule content of cells of several hematopoietic cell lineages.
  • A subgroup of these proteases, including the mast cell chymases, neutrophil cathepsin G, and T cell granzymes B to F and N, are in all investigated mammals encoded in one locus, the chymase locus.
  • This divergence is exemplified by the presence of Mcpt8-related genes and multiple beta-chymases in the mouse and rat, which lack direct counterparts in primates and in seven functional granzyme genes in the mouse where the human locus has only two.
  • To study the expansion of the locus during rodent evolution and to better understand the evolutionary origin of beta-chymases and the Mcpt8-family, we have performed a detailed analysis of the chymase locus of four mammalian species, i.e., human, dog, mouse, and rat.
  • As a result, we report here a second chymase-like gene in dog, Cma2, which clusters with beta-chymases in phylogenetic analyses.
  • This finding supports a duplication of the common ancestor for alpha- and beta-chymases before the major radiation of placental mammals, and a loss of the ancestral beta-chymase gene sometime during primate evolution.
  • Moreover, we show that in the rat, the Mcpt8-family diversified relatively recently together with sequences related to the beta-chymase Mcpt2.
  • Due to the duplications in rat and deletions in the carnivore/primate lineage, the rat chymase locus is approximately 15 and 9 times larger than its counterparts in dog and human, respectively.
  • [MeSH-major] Cell Lineage. Evolution, Molecular. Genetic Variation. Mast Cells / enzymology. Serine Endopeptidases / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Cathepsin G. Cathepsins / genetics. Chymases. Cloning, Molecular. Dogs. Gene Amplification. Genome. Granzymes. Humans. Mice. Molecular Sequence Data. Phylogeny. Primates. Rats. Sequence Homology, Amino Acid

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1984 Nov;83(5):336-9 [6092480.001]
  • [Cites] Genetics. 2000 May;155(1):431-49 [10790415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5767-72 [15790682.001]
  • [Cites] Biochem J. 1995 Oct 15;311 ( Pt 2):675-80 [7487912.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):493-521 [15057822.001]
  • [Cites] J Exp Med. 1997 Jan 6;185(1):13-29 [8996238.001]
  • [Cites] Comput Chem. 1996 Mar;20(1):119-21 [8867843.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 14;1480(1-2):245-57 [10899625.001]
  • [Cites] Eur J Immunol. 2005 Jan;35(1):261-72 [15593300.001]
  • [Cites] J Mol Biol. 2002 Aug 16;321(3):491-502 [12162961.001]
  • [Cites] J Immunol. 1986 Feb 1;136(3):1061-5 [2416825.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):29158-66 [9360993.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):703-15 [11254670.001]
  • [Cites] Eur J Immunol. 2000 Sep;30(9):2660-8 [11009100.001]
  • [Cites] FEBS Lett. 1997 Jul 21;412(1):86-90 [9257695.001]
  • [Cites] Genomics. 1993 Mar;15(3):614-20 [8468056.001]
  • [Cites] Dev Comp Immunol. 2004 Jan;28(1):61-75 [12962983.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19670-6 [10391906.001]
  • [Cites] Science. 2002 Nov 22;298(5598):1610-3 [12446907.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1519-27 [7706457.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39625-31 [12900423.001]
  • [Cites] Science. 1996 Jan 26;271(5248):502-5 [8560264.001]
  • [Cites] J Immunol. 1991 Nov 1;147(9):3210-4 [1919011.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Protein Sci. 1995 Mar;4(3):337-60 [7795518.001]
  • [Cites] J Cell Biochem. 1986;32(1):35-49 [3533969.001]
  • [Cites] Genome Res. 2004 Apr;14(4):609-22 [15060002.001]
  • [Cites] Biochemistry. 1989 Jan 10;28(1):391-5 [2706264.001]
  • [Cites] Nucleic Acids Res. 2000 Nov 1;28(21):4364-75 [11058137.001]
  • [Cites] Biochem Soc Trans. 2005 Apr;33(Pt 2):331-4 [15787599.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14451-6 [8182050.001]
  • [Cites] Immunogenetics. 2004 Aug;56(5):343-54 [15316687.001]
  • [Cites] Nature. 1999 Aug 19;400(6746):769-72 [10466726.001]
  • [Cites] Eur J Immunol. 1991 Jul;21(7):1611-21 [2060576.001]
  • [Cites] Biochemistry. 1987 Nov 3;26(22):6988-94 [3122823.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Mol Biol Evol. 2003 May;20(5):805-14 [12679530.001]
  • [Cites] Curr Opin Immunol. 2003 Oct;15(5):544-52 [14499263.001]
  • [Cites] J Biol Chem. 1993 May 25;268(15):11372-9 [8098710.001]
  • [Cites] FEBS Lett. 2002 Feb 13;512(1-3):133-8 [11852067.001]
  • [Cites] J Biol Chem. 1990 Jan 5;265(1):423-9 [1688433.001]
  • [Cites] Immunology. 1987 Dec;62(4):629-34 [3323034.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1056-61 [12552136.001]
  • [Cites] Science. 1997 Jun 13;276(5319):1687-9 [9180076.001]
  • [Cites] J Immunol. 1996 Nov 1;157(9):4087-93 [8892643.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2438-52 [14583634.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):5377-84 [3549719.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):1022-33 [9541598.001]
  • [Cites] Immunogenetics. 1994;40(6):397-414 [7959952.001]
  • [Cites] Annu Rev Biochem. 1981;50:349-83 [6791577.001]
  • [Cites] J Clin Invest. 1990 Mar;85(3):904-15 [2312733.001]
  • (PMID = 16807746.001).
  • [ISSN] 0093-7711
  • [Journal-full-title] Immunogenetics
  • [ISO-abbreviation] Immunogenetics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.- / Cathepsins; EC 3.4.21.- / GZMB protein, human; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Gzmb protein, mouse; EC 3.4.21.- / Gzmb protein, rat; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.20 / CTSG protein, human; EC 3.4.21.20 / Cathepsin G; EC 3.4.21.20 / Ctsg protein, mouse; EC 3.4.21.20 / Ctsg protein, rat; EC 3.4.21.39 / Chymases; EC 3.4.21.39 / Cma2 protein, mouse
  •  go-up   go-down


70. Singh M, Detamore MS: Biomechanical properties of the mandibular condylar cartilage and their relevance to the TMJ disc. J Biomech; 2009 Mar 11;42(4):405-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomechanical properties of the mandibular condylar cartilage and their relevance to the TMJ disc.
  • Mandibular condylar cartilage plays a crucial role in temporomandibular joint (TMJ) function, which includes facilitating articulation with the TMJ disc, reducing loads on the underlying bone, and contributing to bone remodeling.
  • In this context, development of reliable biomechanical standards for condylar cartilage is crucial.
  • Towards these goals, biomechanical characteristics of the condylar cartilage have been reviewed here, highlighting the structure-function correlations.
  • Structurally, condylar cartilage, like the TMJ disc, exhibits zonal and topographical heterogeneity.
  • Early structural investigations of the condylar cartilage have suggested that the tissue possesses a somewhat transversely isotropic orientation of collagen fibers in the fibrous zone.
  • In a few investigations, condylar cartilage under compression was found to be stiffer anteriorly than posteriorly.
  • [MeSH-major] Cartilage. Mandibular Condyle. Temporomandibular Joint Disc

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200995.001).
  • [ISSN] 1873-2380
  • [Journal-full-title] Journal of biomechanics
  • [ISO-abbreviation] J Biomech
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 116
  •  go-up   go-down


71. Ho T, Sedarat F, Rao N, Pullarkat ST: Diagnostic confusion resulting from CD56 expression by cutaneous myeloid sarcoma. Rare Tumors; 2009;1(2):e51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic confusion resulting from CD56 expression by cutaneous myeloid sarcoma.
  • Myeloid sarcomas are tumor masses composed of aggregates of malignant myeloid precursors in extramedullary sites including the skin.
  • Expression of CD56 by the malignant cells led to an initial misdiagnosis as Merkel cell tumor.
  • Comprehensive pathological evaluation confirmed the diagnosis of myeloid sarcoma with aberrant expression of CD56 and carrying the translocation t(8;21) (q22;q22).
  • Aberrant antigen expression by cutaneous myeloid sarcomas can cause diagnostic confusion with other cutaneous neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139930.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994451
  • [Keywords] NOTNLM ; fluorescent in situ hybridization / myeloid sarcoma / t(8;21) acute myelogenous leukemia.
  •  go-up   go-down


72. Kukko H, Koljonen V, Lassus P, Tukiainen E, Haglund C, Böhling T: Expression of endostatin in merkel cell carcinoma. Anticancer Res; 2007 Jul-Aug;27(4C):2583-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endostatin in merkel cell carcinoma.
  • BACKGROUND: The aim of this study was to examine the expression of endostatin in Merkel cell carcinoma (MCC) and to correlate the expression with tumour growth and the development of metastasis.
  • PATIENTS AND METHODS: The study comprised 19 patients treated for MCC at the Helsinki University Hospital, Helsinki, Finland between 1987 and 2003.
  • The correlations between the quantitative expression of endostatin and tumour parameters were analysed statistically.
  • Endostatin correlated negatively with tumour size, and was expressed in 30% of the large and 56% of the small tumours.
  • The simultaneous expression of vascular endothelial growth factor receptor-2 and endostatin was distinguished in small-sized tumours.
  • CONCLUSION: This study showed a correlation between endostatin expression and small tumour size in Merkel cell carcinoma.
  • This finding was further confirmed by the finding that tumours positive for VEGFR-2, but not for endostatin, seemed to be larger than tumours that showed simultaneous expression of VEGFR-2 and endostatin.
  • [MeSH-major] Carcinoma, Merkel Cell / metabolism. Endostatins / biosynthesis. Skin Neoplasms / metabolism
  • [MeSH-minor] Cell Growth Processes / physiology. Humans. Immunohistochemistry. Neoplasm Metastasis. Vascular Endothelial Growth Factor Receptor-2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695418.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endostatins; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


73. Wang L, Lazebnik M, Detamore MS: Hyaline cartilage cells outperform mandibular condylar cartilage cells in a TMJ fibrocartilage tissue engineering application. Osteoarthritis Cartilage; 2009 Mar;17(3):346-53
Hazardous Substances Data Bank. GLUCOSAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyaline cartilage cells outperform mandibular condylar cartilage cells in a TMJ fibrocartilage tissue engineering application.
  • OBJECTIVE: To compare temporomandibular joint (TMJ) condylar cartilage cells in vitro to hyaline cartilage cells cultured in a three-dimensional (3D) environment for tissue engineering of mandibular condylar cartilage.
  • DESIGN: Mandibular condylar cartilage and hyaline cartilage cells were harvested from pigs and cultured for 6 weeks in polyglycolic acid (PGA) scaffolds.
  • Both types of cells were treated with glucosamine sulfate (0.4 mM), insulin-like growth factor-I (IGF-I) (100 ng/ml) and their combination.
  • At weeks 0 and 6, cell number, glycosaminoglycan (GAG) and collagen content were determined, types I and II collagen were visualized by immunohistochemistry and GAGs were visualized by histology.
  • RESULTS: Hyaline cartilage cells produced from half an order to a full order of magnitude more GAGs and collagen than mandibular condylar cartilage cells in 3D culture.
  • IGF-I was a highly effective signal for biosynthesis with hyaline cartilage cells, while glucosamine sulfate decreased cell proliferation and biosynthesis with both types of cells.
  • In vitro culture of TMJ condylar cartilage cells produced a fibrous tissue with predominantly type I collagen, while hyaline cartilage cells formed a fibrocartilage-like tissue with types I and II collagen.
  • The combination of IGF and glucosamine had a synergistic effect on maintaining the phenotype of TMJ condylar cells to generate both types I and II collagen.
  • CONCLUSION: Given the superior biosynthetic activity by hyaline cartilage cells and the practical surgical limitations of harvesting cells from the TMJ of a patient requiring TMJ reconstruction, cartilage cells from elsewhere in the body may be a potentially better alternative to cells harvested from the TMJ for TMJ tissue engineering.
  • This finding may also apply to other fibrocartilages such as the intervertebral disc and knee meniscus in applications where a mature cartilage cell source is desired.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760638.001).
  • [ISSN] 1522-9653
  • [Journal-full-title] Osteoarthritis and cartilage
  • [ISO-abbreviation] Osteoarthr. Cartil.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibrillar Collagens; 0 / Glycosaminoglycans; 67763-96-6 / Insulin-Like Growth Factor I; N08U5BOQ1K / Glucosamine
  •  go-up   go-down


74. Shibata S, Yokohama-Tamaki T: An in situ hybridization study of Runx2, Osterix, and Sox9 in the anlagen of mouse mandibular condylar cartilage in the early stages of embryogenesis. J Anat; 2008 Sep;213(3):274-83
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An in situ hybridization study of Runx2, Osterix, and Sox9 in the anlagen of mouse mandibular condylar cartilage in the early stages of embryogenesis.
  • Mandibular condylar cartilage is the best-studied mammalian secondary cartilage, differing from primary cartilage in that it originates from alkaline phosphatase-positive progenitor cells.
  • We previously demonstrated that three transcription factors related to bone and cartilage formation, namely Runx2, Osterix and Sox9, are simultaneously expressed in the anlage of mandibular condylar cartilage (condylar anlage) at embryonic day (E)14.
  • In this study, expression of these transcription factors was investigated in the anlagen of mandibular bone (mandibular anlagen) from E11.0 to 14.0.
  • Runx2 mRNA was first expressed in the mandibular anlage at E11.5.
  • Sox9 mRNA was expressed in Meckel's cartilage and its anlagen throughout the experimental period, but not clearly in the mandibular anlagen until E13.0.
  • At E13.5, the condylar anlage was morphologically identified at the posterior end of the mandibular anlage, and enhanced Sox9 mRNA expression was detected here.
  • At this stage, Runx2 and Osterix mRNA were simultaneously detected in the condylar anlage.
  • These results indicate that the Sox9 mRNA-expressing condylar anlage is derived from Runx2/Osterix mRNA-expressing mandibular anlage, and that upregulation of Sox9 in this region acts as a trigger for subsequent condylar cartilage formation.
  • [MeSH-major] Cartilage / embryology. Core Binding Factor Alpha 1 Subunit / genetics. Gene Expression Regulation, Developmental. Mandibular Condyle / embryology. RNA, Messenger / analysis. SOX9 Transcription Factor / genetics. Transcription Factors / genetics

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Dyn. 1999 May;215(1):69-78 [10340758.001]
  • [Cites] Dev Biol. 1997 Mar 1;183(1):108-21 [9119111.001]
  • [Cites] J Anat. 2006 Feb;208(2):169-77 [16441561.001]
  • [Cites] Dev Dyn. 2007 Feb;236(2):426-34 [17191253.001]
  • [Cites] J Anat. 2007 Jul;211(1):8-15 [17555546.001]
  • [Cites] J Anat. 1999 Oct;195 ( Pt 3):321-9 [10580848.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8695-702 [10722711.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2336-46 [9121483.001]
  • [Cites] J Anat. 1997 Feb;190 ( Pt 2):239-60 [9061447.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):174-8 [9171829.001]
  • [Cites] Cell. 1997 May 30;89(5):755-64 [9182763.001]
  • [Cites] Cell. 1997 May 30;89(5):765-71 [9182764.001]
  • [Cites] Dev Dyn. 1997 Aug;209(4):377-86 [9264261.001]
  • [Cites] Anat Embryol (Berl). 1997 Nov;196(5):349-62 [9406838.001]
  • [Cites] J Anat. 1997 Nov;191 ( Pt 4):561-70 [9449075.001]
  • [Cites] EMBO J. 1998 Oct 1;17(19):5718-33 [9755172.001]
  • [Cites] Mech Dev. 1999 Feb;80(2):159-70 [10072783.001]
  • [Cites] Dev Dyn. 1999 Apr;214(4):279-90 [10213384.001]
  • [Cites] Nat Genet. 1999 May;22(1):85-9 [10319868.001]
  • [Cites] J Bone Miner Res. 1999 May;14(5):757-63 [10320524.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):10738-44 [10753864.001]
  • [Cites] Genes Dev. 2001 Feb 15;15(4):467-81 [11230154.001]
  • [Cites] J Cell Biol. 2001 Apr 2;153(1):87-100 [11285276.001]
  • [Cites] Dev Cell. 2001 Aug;1(2):277-90 [11702786.001]
  • [Cites] Cell. 2002 Jan 11;108(1):17-29 [11792318.001]
  • [Cites] J Anat. 2002 Mar;200(Pt 3):309-20 [12033735.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2813-28 [12414734.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9360-5 [12878728.001]
  • [Cites] Development. 2003 Oct;130(19):4729-39 [12925598.001]
  • [Cites] J Anat. 2003 Oct;203(4):425-32 [14620382.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):952-63 [15107406.001]
  • [Cites] Anat Embryol (Berl). 2004 Jul;208(4):273-80 [15156401.001]
  • [Cites] Proc Finn Dent Soc. 1982;78 Suppl 7:1-137 [7184017.001]
  • [Cites] J Anat. 1987 Apr;151:169-88 [3308801.001]
  • [Cites] Nat Genet. 1995 Jan;9(1):15-20 [7704017.001]
  • [Cites] Arch Oral Biol. 1996 Jan;41(1):47-54 [8833590.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):701-12 [8954738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14665-70 [16203988.001]
  • (PMID = 18624832.001).
  • [ISSN] 1469-7580
  • [Journal-full-title] Journal of anatomy
  • [ISO-abbreviation] J. Anat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 1 Subunit; 0 / RNA, Messenger; 0 / SOX9 Transcription Factor; 0 / Sox9 protein, mouse; 0 / Transcription Factors; 0 / osterix protein, mouse
  • [Other-IDs] NLM/ PMC2732041
  •  go-up   go-down


75. He H, Fang W, Liu X, Weiss LM, Chu PG: Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):40-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases.
  • The pathologic diagnosis of Merkel cell carcinoma (MCC) is mainly based on routine morphology and a characteristic cytokeratin 20 (CK20) immunohistochemical staining pattern.
  • However, about 10% to 15% of MCCs are reportedly CK20 negative and about 10% to 20% of MCCs have only focal CK20 positivity.
  • We aimed to study glypican-3 (GPC3) expression in MCC and to compare it with CK20 expression in MCC.
  • Immunohistochemical expression of GPC-3, CK20, and CD23 were studied in 55 cases of MCC and 21 cases of noncutaneous small cell neuroendocrine carcinoma (SCNC), including 10 cases of pulmonary SCNC and 11 cases of nonpulmonary SCNC.
  • The results of GPC3 expression in these tumors were then compared with that of CK20.
  • Seventy-seven percent of the positive MCCs (30/39) showed GPC3 immunoreactivity in > or = 30% tumor cells.
  • Of the 55 cases, 53 were positive for CK20 (96%); 49 of them showed CK20 immunoreactivity in > or = 30% tumor cells.
  • All MCC cases were either positive for both GPC3 and CK20 (37 cases) or at least 1 of the markers (18 cases, 16 CK20 only and 2 GPC3 only).
  • All cases of MCC and SCNC were negative for CD23.
  • In conclusion, GPC3 is frequently expressed in SCNC of various origins, in particular in MCC, which, in combination with CK20, may represent another useful marker in the diagnosis of MCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813128.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Keratin-20; 0 / Receptors, IgE
  •  go-up   go-down


76. Weidinger S, Rümmler L, Klopp N, Wagenpfeil S, Baurecht HJ, Fischer G, Holle R, Gauger A, Schäfer T, Jakob T, Ollert M, Behrendt H, Wichmann HE, Ring J, Illig T: Association study of mast cell chymase polymorphisms with atopy. Allergy; 2005 Oct;60(10):1256-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association study of mast cell chymase polymorphisms with atopy.
  • Associations analyses between the promoter polymorphism rs1800875 in the mast cell chymase gene (CMA1) and atopy-related phenotypes have yielded inconsistent results.
  • Subjects were phenotyped by standardized questionnaires and interviews, skin prick testing and serum IgE measurements.
  • Two of these haplotypes showed a borderline-significant association with atopic eczema, which did not remain significant after correction for multiple testing.
  • [MeSH-major] Dermatitis, Atopic / genetics. Genetic Predisposition to Disease. Mast Cells / enzymology. Polymorphism, Single Nucleotide / genetics. Serine Endopeptidases / genetics
  • [MeSH-minor] Chymases. Female. Genotype. Humans. Immunoglobulin E / blood. Male. Middle Aged. Phenotype. Promoter Regions, Genetic. Sequence Analysis, DNA. Skin Tests. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16134991.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 37341-29-0 / Immunoglobulin E; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.39 / CMA1 protein, human; EC 3.4.21.39 / Chymases
  •  go-up   go-down


77. Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, Liang WC, Prabhu S, Stephan JP, Hongo JA, Dere RC, Deng R, Cullen M, de Tute R, Bennett F, Rawstron A, Jack A, Ebens A: Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia; 2010 Sep;24(9):1566-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
  • Antibody-drug conjugates (ADCs) are potent cytotoxic drugs linked to antibodies through chemical linkers, and allow specific targeting of drugs to neoplastic cells.
  • The expression of CD22 is limited to B-cells, and we show that CD22 is expressed on the vast majority of non-Hodgkin's lymphomas (NHLs).
  • An ideal target for an ADC for the treatment of NHL would have limited expression outside the B-cell compartment and be highly effective against NHL.
  • We generated an ADC consisting of a humanized anti-CD22 antibody conjugated to the anti-mitotic agent maytansine with a stable linker (anti-CD22-MCC-DM1).
  • Anti-CD22-MCC-DM1 was broadly effective in in vitro killing assays on NHL B-cell lines.
  • We show that anti-CD22-MCC-DM1 was capable of inducing complete tumor regression in NHL xenograft mouse models.
  • Further, anti-CD22-MCC-DM1 was well tolerated in cynomolgus monkeys and substantially decreased circulating B-cells as well as follicle size and germinal center formation in lymphoid organs.
  • These results suggest that anti-CD22-MCC-DM1 has an efficacy, safety and pharmacodynamic profile that support its use as a treatment for NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596033.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoconjugates; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


78. Grabowski J, Saltzstein SL, Sadler GR, Tahir Z, Blair S: A comparison of merkel cell carcinoma and melanoma: results from the california cancer registry. Clin Med Oncol; 2008;2:327-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of merkel cell carcinoma and melanoma: results from the california cancer registry.
  • INTRODUCTION: Melanoma and Merkel cell carcinoma (MCC) are both aggressive skin malignancies associated with immunosuppression and possible UV exposure.
  • Both tumors get similar surgical treatment; however, MCC is a relatively rare tumor in which less is known about prognosis and clinical behavior.
  • METHODS: The California Cancer Registry (CCR), a population-based registry, was reviewed from the years 1988-2003.
  • Merkel cell carcinoma and melanoma were compared with relation to gender, age, ethnicity, disease stage, site, and survival.
  • RESULTS: A total of 113,187 cases of melanoma and 1,878 cases of MCC were identified in the CCR.
  • Though both cancers are more common in men than in women, MCC had a higher incidence in men than melanoma (63% vs 57% p < 0.005).
  • MCC occurs in the more elderly, with 73.6% of cases occurring in people over 70 years.
  • MCC shows a predilection for the head and neck compared to melanoma (47% vs 25.8%) Additionally, melanoma occurs more frequently on the trunk than MCC (30% vs 8.7%).
  • Finally, the 10-year cumulative survival is lower for MCC than for melanoma (17.7% vs 61.3%, p < 0.005).
  • CONCLUSION: Many clinicians assume MCC and melanoma behave similarly.
  • However, MCC occurs in an older population, more frequently on the head and neck, in a higher percentage of men.
  • Additionally, MCC has a higher rate of regional metastasis and thus may have more of a benefit from regional staging procedures.
  • Overall, MCC has a worse prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8 [10067813.001]
  • [Cites] J Cancer Educ. 2000 Spring;15(1):38-40 [10730802.001]
  • [Cites] Stat Med. 2000 Jul 15;19(13):1729-40 [10861774.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):755-67 [11050578.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1307-17 [17005948.001]
  • [Cites] Dermatol Surg. 1999 Jan;25(1):23-5 [9935088.001]
  • [Cites] J Cancer Educ. 2002 Spring;17(1):7-11 [12000111.001]
  • [Cites] Head Neck. 2002 Nov;24(11):982-8 [12410532.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4371-6 [14645427.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):593-9 [15465461.001]
  • [Cites] Am J Clin Oncol. 2004 Oct;27(5):510-5 [15596922.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] World J Surg Oncol. 2006;4:7 [16466578.001]
  • [Cites] J Cancer Educ. 2005 Winter;20(4):240-6 [16497137.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):78-80 [16875943.001]
  • [Cites] J Cancer Educ. 1990;5(2):85-9 [2206936.001]
  • [Cites] J Dermatol Surg Oncol. 1977 Jan-Feb;3(1):30-1 [325045.001]
  • [Cites] J Natl Cancer Inst. 1984 Jul;73(1):75-82 [6588237.001]
  • [Cites] Am J Epidemiol. 1995 May 15;141(10):923-33 [7741122.001]
  • [Cites] Melanoma Res. 1994 Apr;4(2):79-85 [8069100.001]
  • [Cites] J Cancer Educ. 1993 Winter;8(4):313-8 [8186082.001]
  • [Cites] Aust N Z J Surg. 1998 May;68(5):354-8 [9631909.001]
  • (PMID = 21892294.001).
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P60 MD000220; United States / NCI NIH HHS / CA / R25 CA065745; United States / NCI NIH HHS / CA / U56 CA092079; United States / NCI NIH HHS / CA / U56 CA092081
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161663
  • [Keywords] NOTNLM ; california cancer registry / melanoma / merkel cell carcinoma / skin cancer
  •  go-up   go-down


79. Chen ZQ, Huang Z, He TW, Lu TT, Liang XD, He SH: [Prokaryotic expression of human mast cell chymase gene and preparation of its polyclonal antibody]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov;23(11):1025-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prokaryotic expression of human mast cell chymase gene and preparation of its polyclonal antibody].
  • AIM: To express the human mast cell chymase cDNA in E.coli and prepare the antibody against human mast cell chymase with recombinant chymase.
  • METHODS: The human mast cell chymase cDNA was cloned by RT-PCR.
  • The recombinant chymase was expressed in E.coli with L-Arabinose induction and purified by Ni-NTA agarose column.
  • Then the purified chymase was used as immunogen to immunize the rabbit.
  • The titer and specificity of the anti-chymase antibody from the rabbit were analyzed by indirect ELISA and Western blot, respectively.
  • RESULTS: The recombinant chymase was successfully expressed in E.coli, and the polyclonal anit-chymase antibody was prepared by immunizing the rabbit with the purified recombinant chymase.
  • Western blot analysis showed this antibody bound specifically with chymase.
  • CONCLUSION: The anti-chymase antibody from the rabbit with high titer and specificity has been prepared with purified recombinant chymase as immunogen, which lays a foundation for further research into detection and function of chymase.
  • [MeSH-major] Chymases / genetics. Chymases / immunology. Escherichia coli / genetics. Immune Sera / immunology. Mast Cells / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988583.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Immune Sera; EC 3.4.21.39 / Chymases
  •  go-up   go-down


80. Sudakin V: Purification of the mitotic checkpoint complex (MCC) and the anaphase promoting complex/cyclosome (APC/C) from HeLa cells. Cold Spring Harb Protoc; 2010 Jun;2010(6):pdb.prot5449

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification of the mitotic checkpoint complex (MCC) and the anaphase promoting complex/cyclosome (APC/C) from HeLa cells.
  • In this protocol, active anaphase promoting complex/cyclosome (APC/C) and its inhibitor, mitotic checkpoint complex (MCC), are purified from HeLa cell extracts.
  • The MCC is further purified by an additional gel filtration step.
  • The APC/C activity and the ability of MCC to inhibit the APC/C are assayed at every stage of the purification procedure by in vitro ubiquitination assays.
  • [MeSH-major] Biochemistry / methods. Cell Cycle Proteins / isolation & purification. Mitosis. Ubiquitin-Protein Ligase Complexes / isolation & purification
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Cell Extracts. Chemical Fractionation. Chromatography, Gel. Chromatography, High Pressure Liquid. Chromatography, Ion Exchange. HeLa Cells. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20516187.001).
  • [ISSN] 1559-6095
  • [Journal-full-title] Cold Spring Harbor protocols
  • [ISO-abbreviation] Cold Spring Harb Protoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cell Extracts; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


81. Schmitt W, Ramp U: [Merkel cell carcinoma of the upper lid]. Mund Kiefer Gesichtschir; 2006 Nov;10(6):419-22
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma of the upper lid].
  • [Transliterated title] Das Merkel-Zell-Karzinom des Oberlides.
  • AIMS: Merkel cell carcinoma (MCC) of the skin is a rare form of cutaneous malignancy of neuroendocrine origin with a propensity to form cutaneous and lymphogenous metastases.
  • The tumor, affecting predominately elderly patients, has a significantly higher incidence in female patients (80%) compared to male patients (20%).
  • CASE REPORT: A case of a 78-year-old patient with a MCC of the upper lid without lymph node involvement or distant metastasis is described.
  • The tumor was resected and the defect closed by a temporal skin flap performing a temporary cantholysis.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Eyelid Neoplasms / diagnosis. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1993 Feb;16(1):54-7 [8424405.001]
  • [Cites] Dtsch Med Wochenschr. 1997 Jun 6;122(23):753-6 [9229553.001]
  • [Cites] Front Radiat Ther Oncol. 2006;39:68-74 [16394670.001]
  • [Cites] Am J Clin Oncol. 1993 Apr;16(2):102-4 [7680840.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):546-51 [16164706.001]
  • [Cites] Hautarzt. 1998 Oct;48 Suppl 1:S27-9 [9866045.001]
  • [Cites] Chirurg. 2001 Apr;72(4):396-401 [11357530.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):881-5 [9307187.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • (PMID = 17028844.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Brunner M, Thurnher D, Pammer J, Heiduschka G, Petzelbauer P, Schmid C, Schneider S, Erovic BM: Expression of hedgehog signaling molecules in Merkel cell carcinoma. Head Neck; 2010 Mar;32(3):333-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hedgehog signaling molecules in Merkel cell carcinoma.
  • METHODS: One tissue microarray with triplets of 28 samples from 25 patients with Merkel cell carcinoma (MCC) was constructed.
  • Six samples of normal skin and 5 samples of normal oral mucosa served as controls.
  • RESULTS: All investigated proteins were frequently and intensely overexpressed in MCCs (Sonic hedgehog, 93%; Indian hedgehog, 84%; Patched, 86%; Smoothened, 79%; Gli-1, 79%; Gli-2, 79%; Gli-3, 86%) compared with control samples.
  • CONCLUSIONS: Our results indicate that the Hedgehog signaling pathway is strongly activated in MCC and thus may play a role in carcinogenesis.
  • [MeSH-major] Carcinoma, Merkel Cell / metabolism. Head and Neck Neoplasms / metabolism. Hedgehog Proteins / metabolism. Receptors, Cell Surface / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644931.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / GLI3 protein, human; 0 / Hedgehog Proteins; 0 / IHH protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SHH protein, human; 0 / SMO protein, human; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


83. Jia YQ, Liu T, Xu CG, Niu T, Meng WT, Lu JC, Wang H, Leng YM: [Comparison of the long term results between two conditioning regimens MCC and BuCy in chronic myelocytic leukemia after allogeneic stem cell transplantation]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar;37(2):226-9
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the long term results between two conditioning regimens MCC and BuCy in chronic myelocytic leukemia after allogeneic stem cell transplantation].
  • OBJECTIVE: To observe and evaluate the long term survival of patients with chronic myelocytic leukemia transplanted with MCC and BuCy conditioning regimens.
  • METHODS: Fourteen cases were treated with MCC regimen (Melphanlan 170 mg/m2 x d x 1, MeCCNU 400 mg/m2 x d x 1, CTX 60 mg/kg x d x 2) and the median follow up time was 6 years; 16 cases were treated with BuCy regimen (Busulfan 4 mg/kg x d x 4, CTX 60 mg/kg x d x 2) and the median follow up time was 4 year.
  • 4 of 10 patients examined in MCC group showed mixed chimerism at day 100 after transplantation, whereas only 1 of 12 patients examined in BuCy group showed mixed chimerism.
  • The 5-year disease-free survival rate was 71.4% for MCC group and 62.5% for BuCy group.
  • The transplant related mortality and relapse rate were 21% and 7% for MCC group, whereas those were 25% and 12% for BuCy group, respectively.
  • The regimen related toxicity was relatively lower in MCC group and the median duration of hospitalization was 39 days (25-55 days) for patients with MCC regimen, and 55 days (39-90 days) for BuCy regimen.
  • CONCLUSION: MCC regimen has a partial ablative effect on CML and the long term disease-free survival is the same as that of BuCy regimen.
  • In regard to the cost-effect efficacy, MCC regimen has a substantial advantage over BuCy regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Semustine / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. Semustine .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608081.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 13909-09-6 / Semustine; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  •  go-up   go-down


84. Krasagakis K, Krüger-Krasagakis S, Tzanakakis GN, Darivianaki K, Stathopoulos EN, Tosca AD: Interferon-alpha inhibits proliferation and induces apoptosis of merkel cell carcinoma in vitro. Cancer Invest; 2008 Jul;26(6):562-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha inhibits proliferation and induces apoptosis of merkel cell carcinoma in vitro.
  • Merkel cell carcinoma is a tumor with aggressive biological behavior and limited response to chemotherapy.
  • The present study investigated the effect of interferon (IFN)-alpha on growth and apoptosis of Merkel carcinoma cells in vitro.
  • Proliferation of MCC-1 cell line was reduced dose-dependently by IFN-alpha and diminished when higher IFN-alpha concentrations were used.
  • Additionally, IFN-alpha potently decreased DNA-synthesis and Ki67/MIB-1 proliferation index of MCC-1 cultures.
  • Furthermore, IFN-alpha induced dose-dependently apoptosis of MCC-1 cells as shown by caspase-3 activation, and detection of apoptotic DNA strand breaks and fragmented nuclei.
  • These findings suggest that IFN-alpha may have antitumor activity against Merkel cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Carcinoma, Merkel Cell / pathology. Cell Proliferation / drug effects. Interferon-alpha / pharmacology. Merkel Cells / drug effects. Skin Neoplasms / pathology
  • [MeSH-minor] Caspase 3 / metabolism. Cell Line, Tumor. DNA Breaks. DNA Replication / drug effects. Dose-Response Relationship, Drug. Enzyme Activation. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Receptor, Interferon alpha-beta / drug effects. Receptor, Interferon alpha-beta / metabolism. Recombinant Proteins. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584346.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ki-67 Antigen; 0 / Recombinant Proteins; 156986-95-7 / Receptor, Interferon alpha-beta; 76543-88-9 / interferon alfa-2a; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


85. Badertscher K, Brönnimann M, Karlen S, Braathen LR, Yawalkar N: Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol Res; 2005 Apr;296(10):503-6
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis.
  • Mast cell chymase is a chymotrypsin-like serine proteinase primarily stored in secretory mast cell granules.
  • Mast cell chymase has various effects on angiotensin, metalloproteases, lipoproteins, procollagen, neuropeptides and cytokines.
  • Recent studies have demonstrated that chymase inhibitors inhibit skin inflammation.
  • In this study we sought to determine the role of mast cell chymase in atopic dermatitis (AD) in comparison with its role in psoriasis and normal skin.
  • Skin biopsy specimens were obtained from non-lesional and lesional skin of patients with chronic AD and psoriasis and from normal skin of non-atopic and non-psoriatic controls.
  • The number of mast cells containing chymase was determined by immunohistochemistry using a chymase-specific monoclonal antibody.
  • A significantly (P < 0.05) enhanced number of chymase-positive cells was found in lesional AD skin as compared to normal skin as well as to lesional and non-lesional skin of patients with psoriasis.
  • A significant (P < 0.05) increase in the number of chymase-positive cells was also found in non-lesional AD skin in comparison to psoriasis.
  • An enhanced, albeit not statistically significant difference was noted in non-lesional AD skin as compared to normal skin.
  • In conclusion, these results suggest that mast cell chymase may play an integral part in eliciting and maintaining cutaneous inflammation in AD but not in psoriasis.
  • The increased proteinase activity of mast cell chymase may also be involved in promoting a skin barrier defect in AD, which subsequently enhances the skin's permeability to allergens and microbes and thereby aggravates the eczema.
  • [MeSH-major] Dermatitis, Atopic / enzymology. Mast Cells / enzymology. Psoriasis / enzymology. Serine Endopeptidases / metabolism
  • [MeSH-minor] Adult. Chymases. Female. Histocytochemistry. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Psoriasis.
  • Genetic Alliance. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15703960.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.39 / Chymases
  •  go-up   go-down


86. Trotter CL, Edmunds WJ: Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making; 2006 Jan-Feb;26(1):38-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
  • BACKGROUND: The meningococcal serogroup C conjugate (MCC) vaccination program has successfully reduced morbidity and mortality from serogroup C disease in England and Wales, owing to high short-term vaccine effectiveness and substantial herd immunity.
  • The latter effect was not accounted for in the previous economic analysis of the MCC program.
  • METHODS: The authors applied a transmission dynamic model, which accounts for herd immunity, to reevaluate the cost-effectiveness of MCC vaccination.
  • The direct and indirect benefits of the MCC vaccine strategy implemented in England and Wales were compared.
  • The cost-effectiveness of alternative MCC vaccine strategies, including future changes to the current schedule, were evaluated.
  • CONCLUSIONS: Models that do not include the indirect effects of vaccination will underestimate the impact of MCC vaccination and may lead to distorted decision making.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16495199.001).
  • [ISSN] 0272-989X
  • [Journal-full-title] Medical decision making : an international journal of the Society for Medical Decision Making
  • [ISO-abbreviation] Med Decis Making
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Meningococcal Vaccines; 0 / Vaccines, Conjugate
  •  go-up   go-down


87. Trotter CL, Edmunds WJ, Ramsay ME, Miller E: Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Hum Vaccin; 2006 Mar-Apr;2(2):68-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
  • The UK meningococcal serogroup C conjugate (MCC) vaccine program has successfully controlled serogroup C disease, due to high vaccine effectiveness and substantial herd immunity.
  • However, children immunised at 2, 3 and 4 months of age receive only short-term direct protection and may be at risk of disease 15 months after vaccination.
  • To investigate this we applied a mathematical model to predict the future epidemiology of serogroup C disease, with and without changes to the immunization schedule.
  • Only a few cases of serogroup C disease were predicted to occur over the next few years because of persisting herd immunity, even without a change to the vaccine schedule.
  • The inclusion of a booster dose is likely to improve the impact of the MCC program and reducing the number of doses in infancy will improve cost-effectiveness and create space in the schedule for the addition of other vaccines.

  • MedlinePlus Health Information. consumer health - Meningococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17012888.001).
  • [ISSN] 1554-8600
  • [Journal-full-title] Human vaccines
  • [ISO-abbreviation] Hum Vaccin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Meningococcal Vaccines; 0 / Vaccines, Conjugate
  •  go-up   go-down


88. Wetzels CT, Hoefnagel JG, Bakkers JM, Dijkman HB, Blokx WA, Melchers WJ: Ultrastructural proof of polyomavirus in Merkel cell carcinoma tumour cells and its absence in small cell carcinoma of the lung. PLoS One; 2009;4(3):e4958
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrastructural proof of polyomavirus in Merkel cell carcinoma tumour cells and its absence in small cell carcinoma of the lung.
  • BACKGROUND: A new virus called the Merkel Cell Polyomavirus (MCPyV) has recently been found in Merkel Cell Carcinoma (MCC).
  • MCC is a rare aggressive small cell neuroendocrine carcinoma primarily derived from the skin, morphologically indistinguishable from small cell lung carcinoma (SCLC).
  • So far the actual presence of the virus in MCC tumour cells on a morphological level has not been demonstrated, and the presence of MCPyV in other small cell neuroendocrine carcinomas has not been studied yet.
  • METHODOLOGY/PRINCIPAL FINDINGS: We investigated MCC tissue samples from five patients and SCLCs from ten patients for the presence of MCPyV-DNA by PCR and sequencing.
  • MCPyV was detected in two out of five primary MCCs.
  • In one MCC patient MCPyV-DNA was detected in the primary tumour as well as in the metastasis, strongly suggesting integration of MCPyV in the cellular DNA of the tumour in this patient.
  • In the primary MCC of another patient viral particles in tumour cell nuclei and cytoplasm were identified by electron microscopy, indicating active viral replication in the tumour cells.
  • CONCLUSIONS/SIGNIFICANCE: Our results strongly suggest that MCPyV is an oncogenic polyomavirus in humans, and is potentially causally related to the development of MCC but not to the morphological similar SCLC.
  • [MeSH-major] Carcinoma, Merkel Cell. Lung Neoplasms. Polyomavirus / ultrastructure. Skin Neoplasms. Small Cell Lung Carcinoma
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Polyomavirus Infections / genetics. Polyomavirus Infections / pathology. Polyomavirus Infections / virology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):246-8 [18650846.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Int J Dermatol. 2003 Sep;42(9):669-76 [12956675.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):593-9 [15465461.001]
  • [Cites] N Engl J Med. 1979 Aug 16;301(7):355-8 [223051.001]
  • [Cites] Ann Intern Med. 1980 Mar;92(3):373-8 [6243896.001]
  • [Cites] Am J Pathol. 1989 Oct;135(4):703-9 [2552814.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] South Med J. 2005 Mar;98(3):345-9 [15813162.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):693-700 [16785371.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4356-65 [16963733.001]
  • [Cites] J Clin Virol. 2007 Sep;40(1):9-14 [17714984.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):375-81 [18280333.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Rev Med Virol. 2008 Mar-Apr;18(2):117-32 [18001004.001]
  • [Cites] Carcinogenesis. 2008 Apr;29(4):840-5 [18310095.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):247-50 [18449881.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):5-21 [18473355.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5009-13 [18593898.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2767-73 [18798277.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):248-50 [18633441.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):497-8 [11853800.001]
  • (PMID = 19305499.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2654729
  •  go-up   go-down


89. Mitani H, Takahashi I, Onodera K, Bae JW, Sato T, Takahashi N, Sasano Y, Igarashi K, Mitani H: Comparison of age-dependent expression of aggrecan and ADAMTSs in mandibular condylar cartilage, tibial growth plate, and articular cartilage in rats. Histochem Cell Biol; 2006 Sep;126(3):371-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of age-dependent expression of aggrecan and ADAMTSs in mandibular condylar cartilage, tibial growth plate, and articular cartilage in rats.
  • A disintegrin and metalloproteinase with thrombospondin motif (adamalysin-thrombospondins, ADAMTS) degrades aggrecan, one of the major extracellular matrix (ECM) components in cartilage.
  • Mandibular condylar cartilage differs from primary cartilage, such as articular and growth plate cartilage, in its metabolism of ECM, proliferation, and differentiation.
  • Mandibular condylar cartilage acts as both articular and growth plate cartilage in the growing period, while it remains as articular cartilage after growth.
  • We hypothesized that functional and ECM differences between condylar and primary cartilages give rise to differences in gene expression patterns and levels of aggrecan and ADAMTS-1, -4, and -5 during growth and aging.
  • We employed in situ hybridization and semiquantitative RT-PCR to identify mRNA expression for these molecules in condylar cartilage and primary cartilages during growth and aging.
  • All of the ADAMTSs presented characteristic, age-dependent expression patterns and levels among the cartilages tested in this study.
  • ADAMTS-5 mainly contributed to ECM metabolism in growth plate and condylar cartilage during growth.
  • ADAMTS-1 and ADAMTS-4 may be involved in ECM turn over in articular cartilage.
  • The results of the present study reveal that ECM metabolism and expression of related proteolytic enzymes in primary and secondary cartilages may be differentially regulated during growth and aging.
  • [MeSH-major] ADAM Proteins / metabolism. Aggrecans / metabolism. Cartilage, Articular / metabolism. Growth Plate / metabolism. Mandibular Condyle / metabolism
  • [MeSH-minor] ADAMTS1 Protein. ADAMTS5 Protein. Age Factors. Amino Acid Sequence. Animals. Cartilage / metabolism. Extracellular Matrix / metabolism. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. In Situ Hybridization. Male. Molecular Sequence Data. RNA, Messenger. Rats. Rats, Inbred WF. Reverse Transcriptase Polymerase Chain Reaction. Sequence Homology, Amino Acid. Tibia / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2001 Feb;198(Pt 2):129-35 [11273038.001]
  • [Cites] J Biol Chem. 1991 Jan 15;266(2):894-902 [1985970.001]
  • [Cites] J Anat. 1987 Apr;151:169-88 [3308801.001]
  • [Cites] Am J Anat. 1988 Jul;182(3):197-214 [3213819.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):93-106 [9202061.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):615-26 [11535123.001]
  • [Cites] Histochem J. 2001 Jan;33(1):25-35 [11352398.001]
  • [Cites] Anat Embryol (Berl). 1996 Nov;194(5):489-500 [8905015.001]
  • [Cites] Acta Anat (Basel). 1992;144(1):59-64 [1514361.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jan;33(1):33-44 [11167130.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):648-52 [15800625.001]
  • [Cites] Histochem Cell Biol. 2003 Jul;120(1):23-32 [12827373.001]
  • [Cites] J Biol Chem. 1999 Mar 5;274(10):6594-601 [10037754.001]
  • [Cites] J Orthop Res. 2002 Mar;20(2):257-66 [11918305.001]
  • [Cites] Science. 1999 Jun 4;284(5420):1664-6 [10356395.001]
  • [Cites] J Clin Invest. 1996 Nov 15;98(10):2292-9 [8941646.001]
  • [Cites] FEBS Lett. 2000 Aug 4;478(3):241-5 [10930576.001]
  • [Cites] Anat Embryol (Berl). 1996 Sep;194(3):247-52 [8849671.001]
  • [Cites] J Anat. 2003 Aug;203(2):235-41 [12924823.001]
  • [Cites] J Biol Chem. 2000 Dec 8;275(49):38885-90 [10986281.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12 ):1553-62 [15983115.001]
  • [Cites] Arthritis Rheum. 1993 Sep;36(9):1214-22 [8216415.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23443-50 [10438522.001]
  • [Cites] Curr Opin Pharmacol. 2002 Jun;2(3):322-9 [12020478.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25791-7 [10827174.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22695-703 [10801887.001]
  • [Cites] J Histochem Cytochem. 1992 Aug;40(8):1139-46 [1619278.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):644-8 [15800624.001]
  • [Cites] Matrix Biol. 2000 Aug;19(4):333-44 [10963994.001]
  • (PMID = 16583222.001).
  • [ISSN] 0948-6143
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aggrecans; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAMTS1 Protein; EC 3.4.24.- / ADAMTS5 Protein; EC 3.4.24.- / Adamts1 protein, rat; EC 3.4.24.- / Adamts5 protein, rat
  •  go-up   go-down


90. Nemoto I, Sato-Matsumura KC, Fujita Y, Natsuga K, Ujiie H, Tomita Y, Kato N, Kondo M, Ohnishi K: Leukaemic dissemination of Merkel cell carcinoma in a patient with systemic lupus erythematosus. Clin Exp Dermatol; 2008 May;33(3):270-2
Genetic Alliance. consumer health - Systemic lupus erythematosus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemic dissemination of Merkel cell carcinoma in a patient with systemic lupus erythematosus.
  • We describe an unusual bone-marrow metastasis of Merkel cell carcinoma (MCC) arising in the right cheek of a 73-year-old woman with systemic lupus erythematosus (SLE) and Sjögren's syndrome, who had been treated with oral prednisolone and methotrexate for 10 years.
  • Her bone marrow had been completely replaced by metastatic MCC cells, and metastatic cytokeratin 20-positive cells were also identified in the peripheral blood.
  • To our knowledge, in the English literature, only six cases have been described previously of MCC bone-marrow involvement.
  • The high incidence of MCC in immunosuppressed patients such as those with SLE has been discussed previously.
  • We consider that immunosuppression might be associated with bone-marrow metastasis, which is a rare form of MCC.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Carcinoma, Merkel Cell / secondary. Facial Neoplasms

  • Genetic Alliance. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18093245.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Palma S, Cavazzini L, Bovo R, Padovani D, Bugli AM, Borrelli M, Martini A: Merkel cell tumour of the external ear. Report of a case. Auris Nasus Larynx; 2007 Jun;34(2):229-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell tumour of the external ear. Report of a case.
  • Merkel cells carcinoma (MCC) is an uncommon skin lesion, considered a malignancy of the neuroendocrine system, which is found mainly in elderly people.
  • MCC is often an aggressive tumour with high tendency for local recurrence, lymph node involvement and distant metastasis.
  • MCC diagnosis is not always easy for its pathological and clinical features and it should always be considered in presence of lymphoma.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Ear Neoplasms / diagnosis. Ear, External
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Fatal Outcome. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Humans. Keratins / analysis. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Magnetic Resonance Imaging. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Parotid Gland / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064866.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


92. Singh M, Detamore MS: Stress relaxation behavior of mandibular condylar cartilage under high-strain compression. J Biomech Eng; 2009 Jun;131(6):061008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stress relaxation behavior of mandibular condylar cartilage under high-strain compression.
  • During temporomandibular joint (TMJ) function, the mandibular condylar cartilage plays a prime role in the distribution and absorption of stresses generated over the condyle.
  • The present study investigates the regional variations in the elastic and equilibrium moduli of the condylar cartilage under high strains using unconfined compression and stress relaxation, with aims to facilitate future tissue engineering studies.
  • Porcine condylar cartilages from five regions (anterior, central, lateral, medial, and posterior) were tested under unconfined compression.
  • A positive correlation between the thickness and stiffness of the cartilage was observed, reflecting that their regional variations may be related phenomena caused in response to cartilage loading patterns.
  • Condylar cartilage was less stiff under compression than in tension.
  • In addition, condylar cartilage under compression appears to behave in a manner similar to the TMJ disc in terms of the magnitude of moduli and drastic initial drop in stress after a ramp strain.
  • [MeSH-major] Cartilage / physiology. Mandibular Condyle / physiology. Models, Biological. Temporomandibular Joint / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449962.001).
  • [ISSN] 0148-0731
  • [Journal-full-title] Journal of biomechanical engineering
  • [ISO-abbreviation] J Biomech Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Sivelli R, Ghirarduzzi A, Del Rio P, Ricci R, Sianesi M: Giant Merkel cell carcinoma of the left arm. Case report. Ann Ital Chir; 2009 Nov-Dec;80(6):489-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant Merkel cell carcinoma of the left arm. Case report.
  • Merkel cell carcinoma is a rare tumor of dermal origin generally found in sun exposed skin.
  • We report the case of a woman of 76 years old presenting a large vascularized Merkel cell carcinoma (MCC) of the left arm lateral to the elbow joint, infiltrating the muscolo-fascial plane who was treated with surgical therapy and post operative radiotherapy.
  • [MeSH-major] Carcinoma, Merkel Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20476686.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


94. Boneh A, Baumgartner M, Hayman M, Peters H: Methylcrotonyl-CoA carboxylase (MCC) deficiency associated with severe muscle pain and physical disability in an adult. J Inherit Metab Dis; 2005;28(6):1139-40
Hazardous Substances Data Bank. L-CARNITINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylcrotonyl-CoA carboxylase (MCC) deficiency associated with severe muscle pain and physical disability in an adult.
  • We present a patient with methylcrotonyl-CoA carboxylase (MCC) deficiency (McKusick 210200) who suffered from severe muscle pain and physical disability, and propose that this disorder be considered in the differential diagnosis of adult patients presenting with muscle pain and weakness.
  • [MeSH-major] Carbon-Carbon Ligases / deficiency. Metabolism, Inborn Errors / diagnosis. Metabolism, Inborn Errors / physiopathology. Muscles / pathology
  • [MeSH-minor] Adolescent. Biopsy. Carnitine / metabolism. Diagnosis, Differential. Female. Humans. Muscular Diseases / diagnosis. Muscular Diseases / enzymology. Pain. Phenotype

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2001 Feb;107(4):495-504 [11181649.001]
  • [Cites] Hum Mutat. 2005 Aug;26(2):164 [16010683.001]
  • [Cites] J Pediatr. 1998 Mar;132(3 Pt 1):519-23 [9544913.001]
  • (PMID = 16435208.001).
  • [ISSN] 0141-8955
  • [Journal-full-title] Journal of inherited metabolic disease
  • [ISO-abbreviation] J. Inherit. Metab. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 6.4.- / Carbon-Carbon Ligases; EC 6.4.1.4 / methylcrotonoyl-CoA carboxylase; S7UI8SM58A / Carnitine
  •  go-up   go-down


95. Gómez-Carracedo A, Souto C, Martínez-Pacheco R, Concheiro A, Gómez-Amoza JL: Microstructural and drug release properties of oven-dried and of slowly or fast frozen freeze-dried MCC-Carbopol pellets. Eur J Pharm Biopharm; 2007 Aug;67(1):236-45
Hazardous Substances Data Bank. THEOPHYLLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microstructural and drug release properties of oven-dried and of slowly or fast frozen freeze-dried MCC-Carbopol pellets.
  • The influence of the procedure and conditions of drying (oven-drying and freeze-drying after slow or fast freezing) and of the CaCl(2) concentration in the wetting liquid on the physical characteristics and drug release behaviour of microcrystalline cellulose (MCC)-carbopol 40:60 pellets containing theophylline or ketoprofen has been evaluated.
  • [MeSH-minor] Acrylic Resins. Calcium Chloride / chemistry. Drug Compounding. Excipients. Freeze Drying. Freezing. Hydrogen-Ion Concentration. Ketoprofen / administration & dosage. Ketoprofen / chemistry. Linear Models. Particle Size. Polyvinyls / chemistry. Porosity. Rheology. Theophylline / administration & dosage. Theophylline / chemistry. Viscosity. X-Ray Diffraction

  • Hazardous Substances Data Bank. CALCIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317125.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Excipients; 0 / Polyvinyls; 0 / microcrystalline cellulose; 9004-34-6 / Cellulose; 9007-20-9 / carboxypolymethylene; 90Y4QC304K / Ketoprofen; C137DTR5RG / Theophylline; M4I0D6VV5M / Calcium Chloride
  •  go-up   go-down


96. Shibata S, Oda T, Abe T, Yamashita Y, Takano Y: Structural features of incremental line-like striations in mandibular condylar cartilage of c-src-deficient mice. Arch Oral Biol; 2006 Nov;51(11):951-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural features of incremental line-like striations in mandibular condylar cartilage of c-src-deficient mice.
  • Mandibular condylar cartilage is sensitive to masticatory force, while mice lacking the c-src gene (c-src-deficient mice) have osteopetrosis and tooth eruption failure.
  • The purpose of this study was to investigate the morphology of the mandibular condyle in these mice, which were maintained with a soft-food diet for 240 days after birth.
  • The condylar head in the c-src-deficient mice showed slight deformity in shape before weaning, but showed remarkable undergrowth after weaning.
  • No significant morphological or histological differences were detected between the mandibular condyle in wild-type mice fed soft food and those fed hard food, indicating that osteopetrosis, as well as abnormal masticatory force, influences the morphology of the mouse mandibular condyle, and that malocclusion rather than dietary consistency may have greater influence.
  • After 70 days, incremental line-like striations consisting of cartilaginous and non-cartilaginous layers were detected in the mandibular condyle of the c-src-deficient mice, but not in the tibial growth plate.
  • These results indicate that the mandibular condyle in the c-src-deficient mice has unique structural features, adding to its deformity.
  • [MeSH-major] Cartilage, Articular / pathology. Genes, src / genetics. Mandibular Condyle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836972.001).
  • [ISSN] 0003-9969
  • [Journal-full-title] Archives of oral biology
  • [ISO-abbreviation] Arch. Oral Biol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / N01-HD-3263
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aggrecans; 106441-73-0 / Osteopontin; 9007-34-5 / Collagen
  •  go-up   go-down


97. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G: A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem; 2005 Mar 11;280(10):9291-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2.
  • Chymases, serine proteases exclusively expressed by mast cells, have been implicated in various pathological conditions.
  • However, the basis for these activities is not known, i.e. the in vivo substrate(s) for mast cell chymase has not been identified.
  • In this study we show that mice lacking the chymase mouse mast cell protease 4 (mMCP-4) fail to process pro-matrix metalloprotease 9 (pro-MMP-9) to its active form in vivo, whereas both the pro and active form of MMP-9 was found in tissues of wild type mice.
  • The present study thus indicates a key role for mast cell chymase in the regulation of pro-MMP-2 and -9 activities.
  • Moreover, the results suggest an important role for mast cell chymase in regulating connective tissue homeostasis.
  • [MeSH-minor] Animals. Chymases. Connective Tissue / enzymology. Enzyme Activation. Lung / enzymology. Matrix Metalloproteinase 9. Mice. Mice, Knockout. Myocardium / enzymology. Protein Processing, Post-Translational

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615702.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Precursors; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / mast cell protease 4; EC 3.4.21.39 / Chymases; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Gelatinases; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.- / pro-matrix metalloproteinase 9; EC 3.4.24.- / progelatinase; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


98. Yom SS, Rosenthal DI, El-Naggar AK, Kies MS, Hessel AC: Merkel cell carcinoma of the tongue and head and neck oral mucosal sites. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jun;101(6):761-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the tongue and head and neck oral mucosal sites.
  • Merkel cell carcinoma (MCC) is an uncommon primarily dermal malignancy of relatively aggressive biologic course.
  • We review this recent experience and present the first reported primary lingual MCC in a 57-year-old caucasian man.
  • We provide a review of oral mucosal MCC and guidelines for histopathologic and immunohistochemical diagnosis.
  • Merkel cell carcinoma should be included in the differential diagnosis of head and neck mucosal lesions, especially if the tumor is submucosal, and MCC may involve the tongue.
  • Mucosal MCC is aggressive, and there is a high risk for local recurrence and regional and distant metastasis.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Head and Neck Neoplasms / pathology. Tongue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731397.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Chromogranin A; 0 / Chromogranins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Synaptophysin; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 46
  •  go-up   go-down


99. Murakami T, Fukunaga T, Takeshita N, Hiratsuka K, Abiko Y, Yamashiro T, Takano-Yamamoto T: Expression of Ten-m/Odz3 in the fibrous layer of mandibular condylar cartilage during postnatal growth in mice. J Anat; 2010 Sep;217(3):236-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ten-m/Odz3 in the fibrous layer of mandibular condylar cartilage during postnatal growth in mice.
  • It has been speculated that the mandibular condyle develops via the differentiation of the fibroblast-like cells covering the condyle into chondrocytes; however, the developmental mechanisms behind this process have not been revealed.
  • We used laser-capture microdissection and cDNA microarray analysis to elucidate the genes that are highly expressed in these fibroblast-like cells.
  • Among these genes, the transcription of Ten-m/Odz3 was significantly increased in the fibroblast-like cells compared with other cartilage tissues.
  • For the first time, we describe the temporal and spatial expression of Ten-m/Odz3 mRNA in relation to the expression of type I, II, and X collagen mRNA, as determined by in-situ hybridization in mouse mandibular condylar cartilage and mouse femoral cartilage during the early stages of development.
  • Furthermore, we evaluated the in-vitro expression of Ten-m/Odz3 using ATDC5 cells, a mouse chondrogenic cell line.
  • Ten-m/Odz3 was expressed during the early stage of the differentiation of mesenchymal cells into chondrocytes.
  • These findings suggest that Ten-m/Odz3 is involved in the differentiation of chondrocytes and that it acts as a regulatory factor in the early stages of the development of mandibular condylar cartilage.
  • [MeSH-major] Cartilage / metabolism. Mandibular Condyle / metabolism. Membrane Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Animals. Cartilage, Articular / cytology. Cartilage, Articular / growth & development. Cartilage, Articular / metabolism. Cell Differentiation / physiology. Cell Line. Chondrocytes / cytology. Chondrocytes / metabolism. Collagen / genetics. Collagen / metabolism. Gene Expression Regulation, Developmental. Mice. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2003 Mar;130(5):1003-15 [12538525.001]
  • [Cites] Oral Dis. 2008 Jan;14(1):45-50 [18173448.001]
  • [Cites] J Cell Sci. 2003 Mar 1;116(Pt 5):857-66 [12571283.001]
  • [Cites] J Bone Miner Metab. 2003;21(3):145-53 [12720048.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41227-36 [12893825.001]
  • [Cites] Neuropeptides. 2003 Oct;37(5):316-8 [14607109.001]
  • [Cites] J Craniomaxillofac Surg. 2003 Dec;31(6):356-61 [14637064.001]
  • [Cites] Arch Oral Biol. 2004 Feb;49(2):109-18 [14693204.001]
  • [Cites] Arch Oral Biol. 1965 Jul-Aug;10(4):579-84 [4225253.001]
  • [Cites] Arch Oral Biol. 1966 May;11(5):493-500 [5226952.001]
  • [Cites] Anat Rec. 1972 Apr;172(4):659-67 [5027572.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Histochemistry. 1990;93(6):593-9 [2184152.001]
  • [Cites] Cell Tissue Res. 1990 May;260(3):513-20 [2372810.001]
  • [Cites] Mamm Genome. 1991;1(3):171-83 [1797232.001]
  • [Cites] Mech Dev. 1993 Mar;40(3):165-76 [7684246.001]
  • [Cites] Biochem J. 1993 May 15;292 ( Pt 1):57-62 [7684899.001]
  • [Cites] Cell. 1994 May 20;77(4):587-98 [7514504.001]
  • [Cites] EMBO J. 1994 Aug 15;13(16):3728-40 [8070401.001]
  • [Cites] J Cell Biol. 1996 Apr;133(2):457-68 [8609176.001]
  • [Cites] Dev Biol. 1997 May 1;185(1):104-18 [9169054.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 9;235(1):142-7 [9196051.001]
  • [Cites] J Bone Miner Res. 1997 Jan;12(1):52-8 [9240725.001]
  • [Cites] Gene. 1997 Oct 24;200(1-2):59-74 [9373139.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3619-30 [9649432.001]
  • [Cites] J Dent Res. 1999 Jan;78(1):11-9 [10065941.001]
  • [Cites] J Cell Sci. 1999 Jun;112 ( Pt 12):2019-32 [10341219.001]
  • [Cites] Mech Dev. 1999 Sep;87(1-2):223-7 [10495292.001]
  • [Cites] J Dent Res. 2005 Aug;84(8):691-9 [16040724.001]
  • [Cites] Front Biosci. 1999 Dec 1;4:D849-58 [10577396.001]
  • [Cites] J Anat. 1999 Oct;195 ( Pt 3):321-9 [10580848.001]
  • [Cites] Dev Biol. 1999 Dec 1;216(1):195-209 [10588872.001]
  • [Cites] Dev Biol. 2000 Jan 1;217(1):107-20 [10625539.001]
  • [Cites] Int J Dev Biol. 2000 Apr;44(3):309-16 [10853827.001]
  • [Cites] Matrix Biol. 2000 Sep;19(5):389-94 [10980415.001]
  • [Cites] J Cell Sci. 2000 Oct;113 ( Pt 20):3583-91 [11017874.001]
  • [Cites] Gene. 2000 Oct 17;257(1):87-97 [11054571.001]
  • [Cites] Dev Dyn. 2001 Jan;220(1):27-39 [11146505.001]
  • [Cites] Bone. 2001 Apr;28(4):404-9 [11336921.001]
  • [Cites] Osteoarthritis Cartilage. 2001;9 Suppl A:S69-75 [11680692.001]
  • [Cites] Development. 2002 Apr;129(8):1913-24 [11934857.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26128-35 [12000766.001]
  • [Cites] J Anat. 2006 Feb;208(2):169-77 [16441561.001]
  • [Cites] Dev Biol. 2006 Feb 15;290(2):237-45 [16406038.001]
  • [Cites] Anat Sci Int. 2002 Dec;77(4):237-46 [12557419.001]
  • (PMID = 20636325.001).
  • [ISSN] 1469-7580
  • [Journal-full-title] Journal of anatomy
  • [ISO-abbreviation] J. Anat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Tenm3 protein, mouse; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2972537
  •  go-up   go-down


100. Sun J, Zhang J, Lindholt JS, Sukhova GK, Liu J, He A, Abrink M, Pejler G, Stevens RL, Thompson RW, Ennis TL, Gurish MF, Libby P, Shi GP: Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation; 2009 Sep 15;120(11):973-82
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation.
  • BACKGROUND: Mast cell chymase may participate in the pathogenesis of human abdominal aortic aneurysm (AAA), yet a direct contribution of this serine protease to AAA formation remains unknown.
  • METHODS AND RESULTS: Human AAA lesions had high numbers of chymase-immunoreactive mast cells.
  • Serum chymase level correlated with AAA growth rate (P=0.009) in a prospective clinical study.
  • In experimental AAA produced by aortic elastase perfusion in wild-type (WT) mice or those deficient in the chymase ortholog mouse mast cell protease-4 (mMCP-4) or deficient in mMCP-5 (Mcpt4(-/-), Mcpt5(-/-)), Mcpt4(-/-) but not Mcpt5(-/-) had reduced AAA formation 14 days after elastase perfusion.
  • AAA lesions in Mcpt4(-/-) mice had fewer inflammatory cells and less apoptosis, angiogenesis, and elastin fragmentation than those of WT mice.
  • Although Kit(W-sh/W-sh) mice had protection from AAA formation, reconstitution with mast cells from WT mice, but not those from Mcpt4(-/-) mice, partially restored the AAA phenotype.
  • Mechanistic studies suggested that mMCP-4 regulates expression and activation of cysteine protease cathepsins, elastin degradation, angiogenesis, and vascular cell apoptosis.
  • CONCLUSIONS: High chymase-positive mast cell content in human AAA lesions, greatly reduced AAA formation in Mcpt4(-/-) mice, and significant correlation of serum chymase levels with human AAA expansion rate suggests participation of mast cell chymase in the progression of human and mouse AAA.

  • Genetic Alliance. consumer health - Abdominal Aortic Aneurysm.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5545-52 [10681534.001]
  • [Cites] Atherosclerosis. 2009 Jun;204(2):359-64 [18996524.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1605-12 [10841519.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1641-9 [10841523.001]
  • [Cites] J Vasc Surg. 2000 Sep;32(3):519-23 [10957658.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] J Vasc Surg. 2001 Jan;33(1):72-6 [11137926.001]
  • [Cites] Curr Atheroscler Rep. 2002 May;4(3):222-7 [11931720.001]
  • [Cites] Life Sci. 2002 Sep 20;71(18):2195-205 [12204777.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1475-81 [12231569.001]
  • [Cites] Hypertens Res. 2002 Nov;25(6):817-22 [12484503.001]
  • [Cites] J Vasc Surg. 2003 Mar;37(3):628-35 [12618703.001]
  • [Cites] Circ Res. 2003 Mar 21;92(5):493-500 [12600886.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):423-31 [12900518.001]
  • [Cites] J Hypertens. 2004 Jan;22(1):39-42 [15106791.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):879-83 [14960660.001]
  • [Cites] J Cell Biol. 1984 Feb;98(2):534-40 [6693494.001]
  • [Cites] Am J Respir Cell Mol Biol. 1991 Jun;4(6):497-503 [1711351.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18134-40 [8027075.001]
  • [Cites] Br J Dermatol. 1994 Nov;131(5):660-3 [7999597.001]
  • [Cites] J Clin Invest. 1996 Apr 1;97(7):1589-96 [8601622.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3667-70 [8631978.001]
  • [Cites] Int Surg. 1997 Oct-Dec;82(4):398-402 [9412840.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):576-83 [9691094.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1939-46 [9712064.001]
  • [Cites] J Med. 1999;30(1-2):67-74 [10515242.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7285-91 [15905575.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Cardiovasc Res. 2006 Feb 15;69(3):614-24 [16266693.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):6020-9 [16365041.001]
  • [Cites] Exp Cell Res. 2006 May 1;312(8):1289-98 [16460729.001]
  • [Cites] J Pharmacol Sci. 2006;100(5):391-7 [16799256.001]
  • [Cites] Biol Chem. 2006 Aug;387(8):1143-6 [16895486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2855-60 [17301245.001]
  • [Cites] Hypertens Res. 2007 Apr;30(4):349-57 [17541214.001]
  • [Cites] Biol Chem. 2007 Jun;388(6):555-60 [17552902.001]
  • [Cites] Nat Med. 2007 Jun;13(6):719-24 [17546038.001]
  • [Cites] Adv Immunol. 2007;95:167-255 [17869614.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3359-68 [17932568.001]
  • [Cites] Clin Chim Acta. 2008 Feb;388(1-2):214-6 [17964292.001]
  • [Cites] Br J Surg. 2008 Jan;95(1):50-6 [18027383.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):309-14 [18079408.001]
  • [Cites] Int Angiol. 1999 Sep;18(3):193-7 [10688417.001]
  • (PMID = 19720934.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL036110; United States / NHLBI NIH HHS / HL / R01 HL081090-02; United States / NHLBI NIH HHS / HL / R01 HL088547; United States / NHLBI NIH HHS / HL / R01 HL056701; United States / NHLBI NIH HHS / HL / HL60942; United States / NHLBI NIH HHS / HL / HL081090-02; United States / NHLBI NIH HHS / HL / HL56985; United States / NHLBI NIH HHS / HL / R29 HL056701; United States / NHLBI NIH HHS / HL / HL36110; United States / NHLBI NIH HHS / HL / R01 HL060942-10A1; United States / NHLBI NIH HHS / HL / HL88547; United States / NHLBI NIH HHS / HL / HL088547-02; United States / NHLBI NIH HHS / HL / P50 HL056985; United States / NHLBI NIH HHS / HL / HL56701; United States / NHLBI NIH HHS / HL / R01 HL081090; United States / NHLBI NIH HHS / HL / HL060942-10A1; United States / NHLBI NIH HHS / HL / R01 HL088547-02; United States / NHLBI NIH HHS / HL / R01 HL060942; United States / NHLBI NIH HHS / HL / P50 HL083762; United States / NHLBI NIH HHS / HL / HL083762; United States / NHLBI NIH HHS / HL / HL81090
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.- / Cathepsins; EC 3.4.21.- / Cma1 protein, mouse; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / mast cell protease 4; EC 3.4.21.39 / Chymases; EC 3.4.22.27 / cathepsin S
  • [Other-IDs] NLM/ NIHMS130372; NLM/ PMC2757146
  •  go-up   go-down






Advertisement